


THE 15TH ANNUAL

BIOTECH SHOWCASE™

DIGITAL & MEDTECH
MEDICINE & SHOWCASE

SEED SHOWCASE



PRESENTING COMPANY PROFILE GUIDE

Find all the details about the Presenting Companies at Biotech Showcase, Digital Medicine & Medtech Showcase, and Seed Showcase in this guide.

January 9–11, 2023

Co-produced by





DEMY COLTON

WHERE GLOBAL BIOTECH LEADERS CONNECT

 virtualsalons

Year round

 BIOTECH
ceosummit
EUROPE

Spring 2023

 BIOTECH
ceosummit
USA

July 17–19, 2023

 biofuture™

October 2023

**BIOTECH
SHOWCASE™**

January 8–10, 2024

Including Specialized Showcases

**DIGITAL & MEDTECH
MEDICINE & SHOWCASE**

**SEED
SHOWCASE**

**ASIA PACIFIC
SHOWCASE**

demy-colton.com

THE 15TH ANNUAL

BIOTECH SHOWCASE™

DIGITAL & MEDTECH
MEDICINE & SHOWCASE

SEED SHOWCASE

TABLE OF CONTENTS

BIOTECH SHOWCASE™

Profiles 3
Categorical Listings 103

DIGITAL & MEDTECH MEDICINE & SHOWCASE

Profiles 137
Categorical Listings 147

SEED SHOWCASE

Profiles 153
Categorical Listings 179

How to use this book:

This book is divided into 3 sections, Biotech Showcase (BTS), Digital Medicine & Medtech Showcase (DM), and Seed Showcase (S). Each Showcase contains a profile section and categorical listing section. See each abbreviation below which are in bubbles on the right side of each page for quick navigation to each that section.

Abbreviation list:

TOC: Table of Contents

BTS-P : Biotech Showcase Company Profiles


BTS-C: Biotech Showcase Categorical Listing

DM-P: Digital Medicine & Medtech Showcase Profiles

DM-C: Digital Medicine & Medtech Categorical Listing

SEED-P: Seed Profiles

SEED-C: Seed Categorical Listing



THE 15TH ANNUAL

BIOTECH SHOWCASE™

PRESENTING COMPANY
PROFILES

1859, Inc.

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Drug Discovery, Endocrine-Metabolic

Location: San Diego, California United States

Year Established: 2019 **Website:** www.1859.ai

Corporate Partners: Confidential

Funds Raised: \$40M in 2022.

Presenter: Devon Cayer, PhD, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

a:head bio AG

(In-Person)

Categorical Listings: Big Data, CNS-Neurological, Drug Discovery

Location: Vienna, Austria

Year Established: 2019 **Website:** www.aheadbio.com

Corporate Partners: Evotec, Stemcell Technologies, 3Brain AG

Funds Raised: Approximately €8M: €2.5 equity, the rest from public grants.

Presenter: Joshua (Josh) Bagley, PhD, CSO

Aardvark Therapeutics

(In-Person)

Categorical Listings: Drug Discovery, Endocrine-Metabolic, Gastrointestinal

Location: San Diego, California United States

Year Established: 2017 **Website:** www.aardvarktherapeutics.com

Corporate Partners: The company out-licensed a non-core program to Scilex Therapeutics, but the lead program is unencumbered.

Funds Raised: \$49M through Series B.

Presenter: Tien Lee, MD, CEO

Abarceo Pharma

(In-Person)

TOC

Categorical Listings: Autoimmune, Cardiovascular, Endocrine-Metabolic

Location: Malmoe, Sweden

Year Established: 2018 **Website:** www.abarceo.com

Corporate Partners: Company has a collaboration with Eli Lilly (US) around therapeutic mono-clonal anti VDAC1 antibodies. Abarceo has an exclusive license option to develop candidates for diseases of interest.

Funds Raised: €4M in private placement (Seed) rounds.

Presenter: Kristian (Kris) Hansen, PhD, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Abion Inc (KRX:203400)

(In-Person)

Categorical Listings: Antibodies, Infectious Disease, Oncology

Location: Guro-gu, Seoul, South Korea

Year Established: 2007 **Website:** www.abionbio.com

Corporate Partners: TBD

Funds Raised: \$32M from IPO.

Presenter: Tess Lee, CSO

AccuraGen

(In-Person)

Categorical Listings: Diagnostics, Oncology

Location: San Jose, California United States

Year Established: 2013 **Website:** www accuragen.com

Corporate Partners: AccuraGen's MRD product is being developed with MGI, University of Hong Kong, and Shanghai Changzheng Hospital.

Funds Raised: More than \$60M with a \$6.9M series A in 2015 and \$40M series B in 2016.

Presenter: George Cardoza, MBA, CEO

Acelot

(In-Person)

TOC

Categorical Listings: Artificial Intelligence (AI), Bioinformatics, CNS-Neurological

Location: Palo Alto, California United States

Year Established: 2022 **Website:** www.ancelot.com

Corporate Partners: Acelot does not have corporate partners at the moment.

Funds Raised: Recently closed an \$8M Seed round to spin out UCSB Computer Science Professor Ambuj Singh's platform and development compounds.

Presenter: Katie Planey, PhD, MBA, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Actimed Therapeutics Ltd.

(In-Person)

Categorical Listings: Endocrine-Metabolic, Oncology, Orphan-Rare Disease

Location: London, United Kingdom

Year Established: 2017 **Website:** www.actimedtherapeutics.com

Corporate Partners: Actimed currently has no corporate partners.

Funds Raised: \$10M+ in pre-series A funding to date and a further \$3M received in milestone payments in 2021/22.

Presenter: Robin Bhattacharjee, CEO

Activate Therapeutics

(In-Person)

Categorical Listings: Immuno-oncology, Infectious Disease

Location: New Canaan, Connecticut United States

Year Established: 2020 **Website:** www.activatetherapeutics.com

Corporate Partners: Activate does not have any corporate partners.

Funds Raised: Seed funding to date

Presenter: Brian Horsburgh, PhD, CEO

Adagene (NASDAQ:ADAG)

(In-Person)

Categorical Listings: Antibodies, Artificial Intelligence (AI), Immuno-oncology**Location:** San Diego, California United States**Year Established:** 2012 **Website:** www.adagene.com**Corporate Partners:** Exelixis, Sanofi, ADC Therapeutics**Funds Raised:** INP**Presenter:** Peter Luo, PhD, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Adiso Therapeutics Inc

(In-Person)

Categorical Listings: Immunology, Inflammation, Microbiome**Location:** Concord, Massachusetts United States**Year Established:** 2017 **Website:** www.adisotx.com**Corporate Partners:** none**Funds Raised:** Post money on Series A is just over \$40M.**Presenter:** Scott Megaffin, CEO**Adocia Inc.** (Euronext:ADOC)

(In-Person)

Categorical Listings: Drug Delivery, Endocrine-Metabolic, Gene-Cell Therapy**Location:** Lyon, France**Year Established:** 2005 **Website:** www.adocia.com**Corporate Partners:** In April 2018, Adocia granted Tonghua Dongbao licenses to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle-Eastern territories.**Funds Raised:** Approximately €85M since inception.**Presenter:** Olivier Soula, PhD, MBA, Deputy CEO & General Manager

Adora Life Science

(In-Person)

TOC

Categorical Listings: Dermatology, Inflammation, Musculoskeletal

Location: Franklin, Tennessee United States

Year Established: 2019 **Website:** <https://adoralifescience.com/>

Corporate Partners: Company is currently partnering the development of an injectable veterinary product with similarities to the human technology.

Funds Raised: Greater than \$5M but less than \$10M.

Presenter: Thomas (Tom) Dambra, Chairman

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Aelin Therapeutics

(In-Person)

Categorical Listings: Oncology, Platform Technology

Location: Leuven, Belgium

Year Established: 2017 **Website:** www.aelintx.com

Corporate Partners: INP

Funds Raised: Series A of €27M.

Presenter: Els Beirnaert, PhD, CEO

Aeolian Biotechnology Corp.

(In-Person)

Categorical Listings: Infectious Disease, Vaccines

Location: Roca, Nebraska United States

Year Established: 2022 **Website:** www.aeolianbiotech.com

Corporate Partners: None at present.

Funds Raised: INP

Presenter: Tyler Martin, MD, CEO

Aerami Therapeutics

(In-Person)

TOC

Categorical Listings: Cardiovascular, Drug Delivery, Endocrine-Metabolic

Location: Durham, North Carolina United States

Year Established: 2010 **Website:** www.aerami.com

Corporate Partners: INP

Funds Raised: More than \$120M since inception.

Presenter: Lisa Yañez, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

AffyXell Therapeutics, Co., Ltd.

(In-Person)

Categorical Listings: Autoimmune, Gene-Cell Therapy, Immunology

Location: Gwanggyo, South Korea

Year Established: 2020 **Website:** www.affyxell.com

Corporate Partners: Daewoong, Avacta, GenScript ProBio

Funds Raised: \$7M for A in 2021, \$13M for Bridge in 2022, and \$3M South Korea government-funded.

Presenter: Helena Shim, Director, Business Development

AIM Biotech

(In-Person)

Categorical Listings: Diagnostics, Drug Discovery, Gene-Cell Therapy

Location: Singapore

Year Established: 2012 **Website:** www.aimbitech.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Jim McGorry, MBA, CEO

AIMEDBIO INC.

(In-Person)

TOC

Categorical Listings: Antibodies, Artificial Intelligence (AI), Autoimmune

Location: Seoul, South Korea

Year Established: 2018 **Website:** www.aimedbio.com

Corporate Partners: The company's most advanced pipeline is being developed with GeneQuantum, a company specializing in site-specific bioconjugation. They also have various antibody-based oncology pipelines under collaboration with SK Biopharmaceuticals and GC Cell.

Funds Raised: \$5M in Pre-A and more than \$11M in Series A funding since 2019. About \$3M in grants.

Presenter: Do-Hyun Nam, MD, PhD, Founder & CTO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

AIVITA Biomedical, Inc.

(In-Person)

Categorical Listings: Immuno-oncology, Infectious Disease, Personalized Medicine

Location: Irvine, California United States

Year Established: 2016 **Website:** www.aivitabiomedical.com

Corporate Partners: AIVITA's COVID-19 trials were conducted in collaboration with the Indonesia Ministry of Health, which paid all clinical costs.

Funds Raised: \$42M to date in Series B-2. AIVITA is now initiating its Series C round.

Presenter: Hans Keirstead, PhD, Chairman & CEO

Akadeum Life Sciences

(In-Person)

Categorical Listings: Diagnostics, Gene-Cell Therapy, Immunology

Location: Ann Arbor, Michigan United States

Year Established: 2014 **Website:** www.akadeum.com

Corporate Partners: Akadeum works with corporate partners on integrating Akadeum technology into cell therapy, diagnostic, and research products (several in place)- currently identifying partners in cell therapy applications.

Funds Raised: \$25M with Series B of \$17.5M.

Presenter: Brandon H. McNaughton, PhD, CEO

Akari Therapeutics, Plc (NASDAQ:AKTX)

(In-Person)

TOC

Categorical Listings: Autoimmune, Hematology, Immunology

Location: London, United Kingdom

Year Established: 2015 **Website:** www.akaritx.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Rachelle Jacques, President & CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

ALiA BioTech Holdings Limited

(In-Person)

Categorical Listings: Diagnostics, Infectious Disease, Microarrays

Location: Hong Kong, Hong Kong, S.A.R.

Year Established: 2012 **Website:** www.aliabiotech.com

Corporate Partners: ALiA platform is developed in collaboration with The University of Hong Kong, as well as research institutions in the EU, namely Institut Pasteur and Fraunhofer-Gesellschaft

Funds Raised: Total funding to date: \$33M.

Presenter: Kelvin Chiu, MBA, MPhil, CEO

Allergenis

(In-Person)

Categorical Listings: Autoimmune, Bioinformatics, Diagnostics

Location: Hatfield, Pennsylvania United States

Year Established: 2017 **Website:** www.allergenis.com

Corporate Partners: In collaboration with six therapeutic developers focused on food allergy. Partnered with LifeMD (NASDAQ: LFMD) for tele-medicine provider services

Funds Raised: \$18M

Presenter: Jim Garner, CEO

Alpha Tau Medical Ltd. (NASDAQ:DRTS)

(In-Person)

TOC

Categorical Listings: CNS-Neurological, Dermatology, Gastrointestinal**Location:** Jerusalem, Israel**Year Established:** 2015 **Website:** www.alphatau.com**Corporate Partners:** Partnered with MIM Software on treatment planning software. Partnered with HekaBio on Japanese development.**Funds Raised:** More than \$100M in public financing, following over \$70M in private financing before going public.**Presenter:** Raphi Levy, CFO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

AltruBio Inc

(In-Person)

Categorical Listings: Antibodies, Autoimmune, Immunology**Location:** San Francisco, California United States**Year Established:** 2020 **Website:** www.altrubio.com/altrubio/en**Corporate Partners:** Not currently partnered**Funds Raised:** \$63M in company's Series A round.**Presenter:** Judy Chou, PhD, President & CEO**Alveolus Bio**

(In-Person)

Categorical Listings: Fibrosis, Inflammation, Microbiome**Location:** Cambridge, Massachusetts United States**Year Established:** 2020 **Website:** www.alveolusbio.com**Corporate Partners:** Open to and in talks for strategic partnerships**Funds Raised:** \$2.25M Seed from investors and \$5M+ in grants from the National Institutes of Health and the American Heart Association.**Presenter:** Vivek Lal, MD, Founder & CEO

Ambrx Biopharma Inc. (NYSE:AMAM)

(In-Person)

TOC

Categorical Listings: Antibodies, Drug Discovery, Immuno-oncology**Location:** La Jolla, California United States**Year Established:** 2003 **Website:** www.ambrx.com**Corporate Partners:** NovoCodex Biopharma, BeiGene, Sino Biopharm**Funds Raised:** Approx. \$149M in 2021 and \$94M in 2020, from the issuance of shares.**Presenter:** Daniel J. O'Connor, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

AMD Therapeutics LLC

(In-Person)

Categorical Listings: Drug Discovery, Ophthalmic**Location:** Palo Alto, California United States**Year Established:** 2015 **Website:** www.amd-therapeutics.com**Corporate Partners:** Teika Pharmaceutical Co., Ltd. (Japan). BNC Korea.**Funds Raised:** Approximately \$3M**Presenter:** Hiroaki (Hiro) Serizawa, PhD, Founder & CEO**Amplicore Inc.**

(In-Person)

Categorical Listings: Drug Delivery, Musculoskeletal, Regenerative Medicine**Location:** Mason, Ohio United States**Year Established:** 2019 **Website:** www.amplicorepharma.com**Corporate Partners:** Amplicore has been partnering with CROs specialized in the orthopedic domain including MCRA, Inotiv, and WuXi AppTec.**Funds Raised:** More than \$3M in grants awarded, with \$4M Series Seed equity round closed in 2021.**Presenter:** Chia-Ying (James) James Lin, President & CEO

Amplo Biotechnology

(In-Person)

Categorical Listings: Gene-Cell Therapy, Musculoskeletal, Neuropathy

Location: Towson, Maryland United States

Year Established: 2019 **Website:** www.amplobiotechnology.com

Corporate Partners: INP

Funds Raised: More than \$4.5M to date. \$2.3M in equity, \$1.8M in grants, \$0.5M in research funding.

Presenter: Patricio Sepulveda, PhD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Angany Inc.

(In-Person)

Categorical Listings: Antibodies, Immunology, Immuno-oncology

Location: Quebec City, Quebec Canada

Year Established: 2017 **Website:** www.angany.com

Corporate Partners: Partnership with Nextmune (Vimian) (Veterinary)

Funds Raised: >\$18M from private, individual investors. \$2M in up-front/milestones payments.

Presenter: Guy Tropper, MD, SVP, Medical & Corporate Affairs

AnHeart Therapeutics

(In-Person)

Categorical Listings: Oncology, Orphan-Rare Disease

Location: New York, New York United States

Year Established: 2018 **Website:** www.anhearttherapeutics.com

Corporate Partners: INP

Funds Raised: \$100M

Presenter: Lihua Zheng, PhD, CBO

Anima Biotech

(In-Person)

TOC

Categorical Listings: Artificial Intelligence (AI), Big Data, Drug Discovery

Location: Bernardsville, New Jersey United States

Year Established: 2014 **Website:** www.animabiotech.com

Corporate Partners: March 2021: Anima Biotech Announces Strategic Collaboration with Takeda, July 2018: Anima Biotech announces a strategic collaboration with Lilly

Funds Raised: INP

Presenter: Kevin Pong, PhD, CBO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Anixa Biosciences (NASDAQ:ANIX)

(In-Person)

Categorical Listings: Immuno-oncology, Infectious Disease, Oncology

Location: San Jose, California United States

Year Established: 1982 **Website:** www.anixa.com

Corporate Partners: Cleveland Clinic, Moffitt Cancer Center

Funds Raised: INP

Presenter: Mike Catelani, President, COO & CFO

Aptose Biosciences Inc. (NASDAQ:APTO)

(In-Person)

Categorical Listings: Drug Discovery, Epigenetic, Hematology

Location: San Diego, California United States

Year Established: 2014 **Website:** www.aptose.com

Corporate Partners: Crystal Genomics, South Korea; Hanmi Pharmaceutical, South Korea

Funds Raised: \$90M since 2014.

Presenter: William (Bill) Rice, PhD, Chairman, President & CEO

Aqualung Therapeutics Corp

(In-Person)

TOC

Categorical Listings: Antibodies, Autoimmune, Fibrosis

Location: Tucson, Arizona United States

Year Established: 2017 **Website:** www.aqualungtherapeutics.com

Corporate Partners: Seeking corporate partners at this time.

Funds Raised: Approx \$28M NIH Grants; \$3.8M convertible notes, 2019, 2022; \$1.5M Series A Oct 2022.

Presenter: Joe (Skip) GN Garcia, MD, Founder & CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Aqyre Biosciences, Inc.

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Diagnostics, Gastrointestinal

Location: Weston, Massachusetts United States

Year Established: 2019 **Website:** www.aqyre.com

Corporate Partners: Johnson & Johnson

Funds Raised: Aqyre closed on \$22M in Series A fundraising in 2022.

Presenter: Bertrand de Poly, MSc, Co-Founder & CEO

Arch Therapeutics (OTCQX:ARTH)

(In-Person)

Categorical Listings: Dermatology, Platform Technology, Regenerative Medicine

Location: Framingham, Massachusetts United States

Year Established: 2006 **Website:** www.archtherapeutics.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Terrence W. Norchi, MD, President & CEO

Arctoris Ltd

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Machine Learning, Drug Discovery

Location: Oxford, United Kingdom

Year Established: 2016 **Website:** www.arctoris.com

Corporate Partners: Partners include several Top 10 Pharma companies, as well as numerous biotech and AI drug discovery companies in US, Europe, and Asia-Pacific.

Funds Raised: \$10M to date in funding from specialist investors.

Presenter: Martin-Immanuel Bittner, MD, PhD, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Aristea Therapeutics

(In-Person)

Categorical Listings: Autoimmune, Dermatology, Immunology

Location: San Diego, California United States

Year Established: 2018 **Website:** www.aristeatx.com

Corporate Partners: Aristea has a collaboration and option to acquire deal with Pfizer (Arena Pharmaceuticals).

Funds Raised: \$138M through Series A (\$15M), Series B (\$63M) and option to acquire deal (\$60M).

Presenter: James Mackay, PhD, President & CEO

Arovella Therapeutics (ASX:ALA)

(In-Person)

Categorical Listings: Hematology, Immuno-oncology, Oncology

Location: Carlton, Australia

Year Established: 1999 **Website:** www.arovella.com

Corporate Partners: Arovella has licensed its platform and DKK1-Peptide targeting CAR from Imperial College and MD Anderson Cancer Center, respectively. It has a Strategic Collaboration with Imugene Ltd.

Funds Raised: INP

Presenter: Michael James Baker, PhD, MBA, Managing Director & CEO

Ashvattha Therapeutics

(In-Person)

Categorical Listings: CNS-Neurological, Immunology, Neurology

Location: Redwood City, California United States

Year Established: 2015 **Website:** www.avttx.com

Corporate Partners: Huadong Medicine licensed rights to three clinical stage products for China and parts of southeast Asia. Joint development efforts are ongoing.

Funds Raised: \$79M in equity capital; \$45M in non-dilutive partnering.

Presenter: Jeffrey (Jeff) Cleland, PhD, Chairman, CEO & President

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Atmo Biosciences Limited

(In-Person)

Categorical Listings: Big Data, Diagnostics, Drug Delivery

Location: Box Hill, Australia

Year Established: 2018 **Website:** www.atmobiosciences.com

Corporate Partners: Otsuka Pharmaceutical Co. (market development). Clinical Trials: Monash University, Alfred Healthcare, Florida State University, University of Queensland, University of Adelaide, RMIT University; Planet Innovation (product development); C.R.Kennedy (distribution and market development).

Funds Raised: \$11.5M to date, including an upsized, oversubscribed \$7M round in 2021 which included Otsuka Pharmaceutical Co.

Presenter: Malcolm (Mal) Hebblewhite, MBA, CEO

Atriva Therapeutics GmbH

(In-Person)

Categorical Listings: Drug Delivery, Infectious Disease

Location: Frankfurt am Main, Germany

Year Established: 2015 **Website:** www.atriva-therapeutics.com

Corporate Partners: TBA

Funds Raised: €37M Equity & venture loan. Up to €33M non-dilutive grants from German government in 2021/22/23.

Presenter: Rainer Lichtenberger, PhD, MBA, CEO

AUM Biosciences Pte Ltd

(In-Person)

TOC

Categorical Listings: Drug Discovery, Immuno-oncology, Oncology

Location: Bethesda, Maryland United States

Year Established: 2018 **Website:** www.aumbiosciences.com

Corporate Partners: MNK inhibitors are under clinical trial in combination, with pembrolizumab for MSS and CRC and, with anti-PDL1 for NSCLC and urothelial cancer in collaboration with Merck and Roche, respectively.

Funds Raised: \$27M of Series A funding in 2021.

Presenter: Vishal Doshi, MSc, Chairman & CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Autonomous Therapeutics, Inc.

(In-Person)

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Infectious Disease

Location: Rockville, Maryland United States

Year Established: 2017 **Website:** www.autonomous.bio

Corporate Partners: Blue Knight (a joint initiative between Johnson & Johnson and BARDA), DARPA, Office of the Secretary of Defense, Curia Global, Venture Capital

Funds Raised: INP

Presenter: Ariel Weinberger, PhD, CEO

Avectas

(In-Person)

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Platform Technology

Location: Kildare, Ireland

Year Established: 2012 **Website:** www.avectas.com

Corporate Partners: Undisclosed

Funds Raised: In excess of \$50M

Presenter: Michael Maguire, PhD, CEO

Azora Therapeutics Inc

(In-Person)

Categorical Listings: Autoimmune, Dermatology, Gastrointestinal

Location: Los Angeles, California United States

Year Established: 2019 **Website:** www.azoratherapeutics.com

Corporate Partners: None.

Funds Raised: \$8M Series A in 2021.

Presenter: Matthew (Matt) Davidson, PhD, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Baiyaphytopharm Co., Ltd

(In-Person)

Categorical Listings: Antibodies, Immuno-oncology, Infectious Disease

Location: Bangkok, Thailand

Year Established: 2018 **Website:** www.baiyaphytopharm.com

Corporate Partners: The company's vaccine pipeline is being developed in partnership with 3M and AAHL. Some oncology pipelines are being developed in partnership with ImmunityBio.

Funds Raised: \$5M crowd-funding 2020, \$5M crowd-funding 2021, \$7M Grant funding 2022

Presenter: Suthira Taychakhoonavudh, PhD, MSc, CEO

BAKX Therapeutics

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Machine Learning, Oncology

Location: Kingston, New York United States

Year Established: 2000 **Website:** www.baktxtx.com

Corporate Partners: The company's leading asset, partnered with Ipsen S.A., is focused on activating the BAX protein.

Funds Raised: \$25M Series A and \$852M Partnership.

Presenter: Sree Kant, MPH, MBA, Founder & CEO

Bantam Pharmaceutical LLC

(In-Person)

Categorical Listings: Drug Discovery, Functional Genomics, Hematology

Location: Research Triangle Park, North Carolina United States

Year Established: 2015 **Website:** www.bantampharma.com

Corporate Partners: Bantam is currently evaluating corporate partnering options.

Funds Raised: \$27M since company inception in 2015, from high net worth individuals.

Presenter: Michael Stocum, MS, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

BC Platforms

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Bioinformatics, Personalized Medicine

Location: Zurich, Switzerland

Year Established: 1997 **Website:** www.bcplatforms.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Tero Silvola, MSc, CEO

Bexion Pharmaceuticals, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Immuno-oncology, Neuropathy

Location: Covington, Kentucky United States

Year Established: 2006 **Website:** www.bexionpharma.com

Corporate Partners: Bexion is seeking corporate partners.

Funds Raised: Over \$55M Series B investments plus \$6M in NIH grants; \$50M Series C open, with \$26M collected/committed- October 18, 2022.

Presenter: Scott Shively, President & CEO

Bimini Health Tech

(In-Person)

Categorical Listings: Dermatology, Personalized Medicine, Regenerative Medicine

Location: Plano, Texas United States

Year Established: 2013 **Website:** www.biminihealthtech.com

Corporate Partners: Arthrex, Crown Laboratories, Bausch Health

Funds Raised: \$11M

Presenter: Brad Conlan, MSE, EMBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

BioCity Biopharma

(In-Person)

Categorical Listings: Oncology, Renal

Location: Wuxi, China

Year Established: 2017 **Website:** www.biocitypharma.com

Corporate Partners: WuXi Biologics, WuXi AppTec, AstraZeneca

Funds Raised: More than \$70M in 2020

Presenter: Yong-Jiang Hei, MD, PhD, MSc, Co-CEO

Biocytogen Pharmaceuticals Co., Ltd. (HKEX:2315)

(In-Person)

Categorical Listings: Antibodies, Autoimmune, Drug Discovery

Location: Beijing, China

Year Established: 2009 **Website:** en.biocytogen.com.cn

Corporate Partners: Biocytogen's antibody drug development pipeline is being developed in partnership with many companies including RemeGen. Clinical pipeline is being developed in partnership with Top Alliance, TRACON Pharma and Syncromune.

Funds Raised: INP

Presenter: Vivian Tian, PhD, MBA, Sr. Director, Business Development & Licensing, Head of Biocytogen Europe Innovation Center

BioEclipse Therapeutics

(In-Person)

Categorical Listings: Drug Delivery, Drug Discovery, Gene-Cell Therapy

Location: Mountain View, California United States

Year Established: 2016 **Website:** www.bioeclipse.com

Corporate Partners: NKT cell delivery system has the interest of several Biotech partners. The company is also interested in mid-size development partners.

Funds Raised: \$14M in equity and \$8M in CIRM grant funding.

Presenter: Pamela Reilly Contag, PhD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Biometrix Technology Co., Ltd.

(In-Person)

Categorical Listings: Diagnostics, Drug Delivery, Drug Discovery

Location: Chuncheon-si, South Korea

Year Established: 2008 **Website:** www.bmtchip.com

Corporate Partners: So far, all products are developed in-house

Funds Raised: \$15M

Presenter: Taisun Kim, PhD, CEO

BiondVax Pharmaceuticals Ltd (NASDAQ:BVX)

(In-Person)

Categorical Listings: Antibodies, Autoimmune, Biomanufacturing

Location: Jerusalem, Israel

Year Established: 2005 **Website:** www.biondvax.com

Corporate Partners: NanoAb development collaboration and exclusive licensing agreements with Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen, Germany.

Funds Raised: INP

Presenter: Amir Reichman, MSc, MBA, CEO

Biosortia Microbiomics

(In-Person)

Categorical Listings: Artificial Intelligence (AI), CNS-Neurological, Immunology

Location: Hilliard, Ohio United States

Year Established: 2009 **Website:** www.biosortia.com

Corporate Partners: JLABs-SD graduate

Funds Raised: \$10M Grants & \$10M Investors -Including ARPA-E, AFRL, DARPA and just won NIH (09/22).

Presenter: Ross O. Youngs, Founder

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Bio-T

(Virtual)

Categorical Listings: Antibodies, Diagnostics

Location: Istanbul, Turkey

Year Established: 2019 **Website:** www.bio-t.org

Corporate Partners: Clinical trials for identification of antigens for rapid diagnosis of tuberculosis in urine samples concentrated by its product MyMagiCon is supported by Foundation of Innovative New Diagnostics (FIND), www.findx.org.

Funds Raised: \$1M by angel investors. Expecting to receive shortly an EU grant of \$3.5M.

Presenter: Tanil Kocagöz, MD, PhD, Co-Founder

Bioxodes SA

(In-Person)

Categorical Listings: CNS-Neurological, Orphan-Rare Disease

Location: Gosselies, Belgium

Year Established: 2013 **Website:** www.bioxodes.com

Corporate Partners: INP

Funds Raised: €27M to www.biosortia.com Ir-CPI up to the completion of the Phase 1 study.

Presenter: Marc Dechamps, MS, CEO

Bloom Science, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Drug Discovery, Microbiome

Location: San Diego, California United States

Year Established: 2018 **Website:** www.bloomscience.com

Corporate Partners: Duke University, UCLA, Weizmann Institute of Science

Funds Raised: Series A \$12M

Presenter: Christopher Reyes, PhD, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Body Vision Medical

(In-Person)

Categorical Listings: Diagnostics, Machine Learning, Platform Technology

Location: Campbell, California United States

Year Established: 2014 **Website:** www.bodyvisionmedical.com

Corporate Partners: The company partners with key opinion leaders in lung cancer diagnostic and treatment, strategic and marquee-name hospitals.

Funds Raised: Close to \$50M through fundraising series.

Presenter: David Webster, MS, CEO

Bond Biosciences, Inc.

(In-Person)

Categorical Listings: Drug Delivery, Drug Discovery, Gastrointestinal

Location: Parkville, Missouri United States

Year Established: 2015 **Website:** www.bond.bio

Corporate Partners: Bond welcomes opportunities to explore corporate partnership.

Funds Raised: Series B financing closed in Q1 2022.

Presenter: Cory Berkland, PhD, CEO

Boryung Co., Ltd. (KRX:3850)

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Oncology

Location: Seoul, South Korea

Year Established: 1963 **Website:** www.boryung.co.kr/eng/index.do

Corporate Partners: Boryung is looking for development and/or commercial partners for BR2002. Boryung welcomes any proposals to establish and proceed with a deal structure forward for BR2002.

Funds Raised: INP

Presenter: Bong Seog Kim, MD, PhD, CTO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

BrainStorm Cell Therapeutics (NASDAQ:BCLI)

(In-Person)

Categorical Listings: CNS-Neurological, Gene-Cell Therapy, Inflammation

Location: New York, New York United States

Year Established: 2004 **Website:** www.brainstorm-cell.com

Corporate Partners: BrainStorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn® technology through a licensing agreement with Ramot, the technology transfer company of Tel Aviv University.

Funds Raised: INP

Presenter: Chaim Lebovits, CEO

Brenus Pharma

(In-Person)

Categorical Listings: Immuno-oncology, Oncology, Platform Technology

Location: Lyon, France

Year Established: 2014 **Website:** www.brenus-pharma.com

Corporate Partners: 3D Model POC & Companion Test in Eurostars Partnership with In Sphero. Tech transfer including a scale-up with new CDMO experience in GMP : EFS.

Funds Raised: About €7M invested since inception. With €4M in a Seed round (Caisse d'Epargne, BPI, Biojag).

Presenter: Paul Bravetti, PharmD, MSc, CEO

Bridge Biotherapeutics, Inc (KOSDAQ: 288330)

(In-Person)

Categorical Listings: Fibrosis, Inflammation, Oncology**Location:** Seongnam-si, South Korea**Year Established:** 2015 **Website:** www.bridgebiorx.com**Corporate Partners:** INP**Funds Raised:** INP**Presenter:** Pavel Printsev, Director, Business Development

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Brinter Inc

(In-Person)

Categorical Listings: Biomanufacturing, Cardiovascular, Contract Drug Development**Location:** Santa Monica, California United States**Year Established:** 2017 **Website:** www.brinter.com**Corporate Partners:** Bayer, Wake Forest Institute for Regenerative Medicine (WFIRM)**Funds Raised:** INP**Presenter:** Tomi Alapaattikoski, MS, CEO**Bryleos**

(In-Person)

Categorical Listings: Cardiovascular, Endocrine-Metabolic, Hepatic**Location:** Johnson City, Tennessee United States**Year Established:** 2021 **Website:** www.bryleos.com**Corporate Partners:** ISB BioAnalytica (a subsidiary of the Institute for Systems Biology, a Providence affiliate based in Seattle WA)**Funds Raised:** As of 10/26 - \$4.6M**Presenter:** Wendy Komac, MBA, CEO

Caeregen Therapeutics, LLC

(In-Person)

Categorical Listings: Neurology, Ophthalmic, Orphan-Rare Disease

Location: Chapel Hill, North Carolina United States

Year Established: 2010 **Website:** www.caeregen.com

Corporate Partners: Oakland University Eye Research Institute (Rochester, MI); CDMO Wacker Biotech/Chemie AG; CRO Charles River Laboratories; CRO Celerion; CRO BioPharmSpec.

Funds Raised: \$8M from private investor, NIH/NEI and MI funding since initiation of drug program development in 2018.

Presenter: Walter Capone, MBA, President & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Cairn Therapeutics Inc

(In-Person)

Categorical Listings: Oncology

Location: Tucson, Arizona United States

Year Established: 2016 **Website:** www.cairntherapeutics.com

Corporate Partners: No current partners

Funds Raised: \$3.5M grant from NIH. \$7.0M< privately.

Presenter: William Scott Evangelista, Executive Chairman

Calviri, Inc.

(In-Person)

Categorical Listings: Diagnostics, Drug Discovery, Microarrays

Location: Phoenix, Arizona United States

Year Established: 2017 **Website:** www.calviri.com

Corporate Partners: Can be disclosed under NDA

Funds Raised: +\$22M, equity and non dilutive.

Presenter: Stephen Albert Johnston, PhD, Founder

Carina Biotech

(In-Person)

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Oncology

Location: Mawson Lakes, Australia

Year Established: 2016 **Website:** www.carinabiotech.com

Corporate Partners: Carina Biotech's ibody-enabled CAR-T programs are being developed in collaboration with AdAlta.

Funds Raised: \$11M in grants, \$17M in Seed and Series A funding.

Presenter: Deborah Rathjen, PhD, Managing Director & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Carmine Therapeutics

(In-Person)

Categorical Listings: Gene-Cell Therapy, Ophthalmic, Orphan-Rare Disease

Location: Cambridge, Massachusetts United States

Year Established: 2019 **Website:** www.carminetherapeutics.com

Corporate Partners: The company currently has corporate partners. Details available upon request.

Funds Raised: Carmine recently closed an A-1 round of \$12.5M, and is seeking an additional \$12.5M to close out the A round.

Presenter: Don Haut, PhD, CEO

Cartherics Pty Ltd

(In-Person)

Categorical Listings: Immunology, Immuno-oncology, Oncology

Location: Notting Hill, Australia

Year Established: 2015 **Website:** www.cartherics.com

Corporate Partners: ToolGen, Inc. - licensing partner for gene editing technology and gene deletion IP. Peter MacCallum Cancer Centre - development partner for autologous CAR-T products.

Funds Raised: AUD \$45M+, consisting of AUD \$30M+ investment, AUD \$8.5M+ in competitive grant funding and AUD \$7M+ in government tax incentives.

Presenter: Ian Nisbet, PhD, COO

Cayuga Biotech

Categorical Listings: Cardiovascular, Hematology, Orphan-Rare Disease

Location: Mount Vernon, New York United States

Year Established: 2015 **Website:** www.cayugabiotech.com

Corporate Partners: None

Funds Raised: Approximately \$4M

Presenter: Andrea Ashford-Hicks, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

CB Innovations LLC

Categorical Listings: Cardiovascular, Diagnostics, Machine Learning

Location: San Diego, California United States

Year Established: 2017 **Website:** cboothinnovations.com

Corporate Partners: The company does not currently have a corporate partner.

Funds Raised: \$2.5M to date. Seeking \$10M raise Q1 2023.

Presenter: Christian McClung, MD, MPhil, Co-Founder & CMO

(In-Person)

S-P

S-C

CdmoGen Co., Ltd.

Categorical Listings: Biomanufacturing, Contract Drug Development, Contract Manufacturing

Location: Cheongju, South Korea

Year Established: 2015 **Website:** www.cdmogen.com

Corporate Partners: CRG-01 is being developed with Labcorp as a contracted partner.

Funds Raised: ₩20B in funding since its founding in 2015.

Presenter: Steven H. Lee, PhD, Director, R&D

(In-Person)

Cellino Biotech, Inc.

(In-Person)

Categorical Listings: Big Data, Biomanufacturing, Gene-Cell Therapy

Location: Cambridge, Massachusetts United States

Year Established: 2017 **Website:** www.cellinobio.com

Corporate Partners: Cellino is seeking partnership opportunities to scale up personalized stem cell therapy production.

Funds Raised: \$96M total to date, including \$80M Series A in 2022.

Presenter: Nabiha Saklayen, PhD, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Cellply Srl

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Diagnostics, Gene-Cell Therapy

Location: Bologna, Italy

Year Established: 2014 **Website:** www.cellply.com

Corporate Partners: One of the top 10 pharma companies joined Cellply's early access program. Cellply has also partnered with EU/US biotech companies in the cell & gene therapy space.

Funds Raised: More than €11M to date, including €4M in grants. Last round in 2021.

Presenter: Massimo Bocchi, PhD, CEO

Certa Therapeutics

(In-Person)

Categorical Listings: Fibrosis, Immunology, Orphan-Rare Disease

Location: Melbourne, Australia

Year Established: 2018 **Website:** www.certatherapeutics.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Darren Kelly, PhD, CEO

Chimeric Therapeutics (ASX:CHM)

(In-Person)

Categorical Listings: Gastrointestinal, Gene-Cell Therapy, Hematology

Location: Carlton, Australia

Year Established: 2020 **Website:** www.chimerictherapeutics.com

Corporate Partners: Chimeric is currently exploring corporate partnerships.

Funds Raised: INP

Presenter: Jennifer Chow, Managing Director & CEO



Chrysalis BioTherapeutics, Inc.

(In-Person)

Categorical Listings: Inflammation, Pulmonary, Regenerative Medicine

Location: Galveston, Texas United States

Year Established: 2012 **Website:** www.chrysbio.com

Corporate Partners: None. Drug development has been funded through non-dilutive grants and contracts with NIAID, NCI, and BARDA to mitigate effects of radiation exposure (nuclear countermeasure and radiotherapy) and pulmonary disease.

Funds Raised: INP

Presenter: Darrell Carney, PhD, President & CEO

CiMaas

(In-Person)

Categorical Listings: Gene-Cell Therapy, Hematology, Immuno-oncology

Location: Maastricht, Netherlands

Year Established: 2015 **Website:** www.cimaas.com

Corporate Partners: Option to partner with antibody company: cells are fully active with high cytotoxicity after cryopreservation and express high levels of CD16 allowing the combination with antibodies.

Funds Raised: INP

Presenter: Gerard Bos, MD, PhD, CEO

Circio AB

(In-Person)

Categorical Listings: Immunology, Immuno-oncology, Oncology

Location: Hässelby, Sweden

Year Established: 2022 **Website:** www.circio.com

Corporate Partners: Part of the Targovax Group.

Funds Raised: INP

Presenter: Erik Digman Wiklund, PhD, MSc, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Coagulation Sciences

(In-Person)

Categorical Listings: Diagnostics, Hematology, Personalized Medicine

Location: Bronx, New York United States

Year Established: 2002 **Website:** www.coagulationsciences.com

Corporate Partners: Coagulation Sciences has no corporate partner at this time, but has had early conversations with Siemens Healthineers, Abbott, Roche and Haemonetics.

Funds Raised: \$5.4M

Presenter: Sheldon Goldstein, MD, CEO

Combined Therapeutics Inc

(In-Person)

Categorical Listings: Big Data, Immunology, Immuno-oncology

Location: Boston, Massachusetts United States

Year Established: 2017 **Website:** www.combinedtx.com

Corporate Partners: Undisclosed

Funds Raised: INP

Presenter: Romain Micol, MD, MPH, PhD, MBA, President, Co-founder & CEO

Comera Life Sciences, Inc. (NASDAQ:CMRA)

(In-Person)

Categorical Listings: Antibodies, Biosimilars, Drug Delivery

Location: Woburn, Massachusetts United States

Year Established: 2014 **Website:** www.comeralifesciences.com

Corporate Partners: Undisclosed Biotech Partner, Undisclosed Global Pharma Partner, Intas Pharmaceuticals Ltd.

Funds Raised: \$25M total. \$10M from series B in 2021, \$15M PIPE in 2022. Completed SPAC in 2022.

Presenter: Jeffrey (Jeff) Hackman, Chairman, President & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Complete Genomics

(In-Person)

Categorical Listings: Diagnostics, Generics, Genomics

Location: San Jose, California United States

Year Established: 2008 **Website:** www.completegenomics.com

Corporate Partners: Examples of partners include NEB, Twist Bio, Roche, etc.

Funds Raised: INP

Presenter: Rade Drmanac, PhD, CSO

Concarlo Therapeutics Inc.

(In-Person)

Categorical Listings: Oncology, Women's Health

Location: Brooklyn, New York United States

Year Established: 2017 **Website:** www.concarlo.com

Corporate Partners: Lead candidate is moving through CMC in partnership with Bachem and Exelead. Small Molecule program is being developed in partnership with Ceptor Biopartners and Curia (formerly AMRI).

Funds Raised: \$7M through Seed funding since inception.

Presenter: Stacy Blain, PhD, Co-Founder & CSO

Congruence Therapeutics

(In-Person)

TOC

Categorical Listings: Artificial Intelligence (AI), CNS-Neurological, Drug Discovery

Location: Saint-Laurent, Quebec Canada

Year Established: 2021 **Website:** www.congruencetx.com

Corporate Partners: Seeking Pharma partnerships in the near future, and will consider both asset-based partnerships as well as R&D discovery collaborations featuring the use of the company's Revenir™ product engine.

Funds Raised: Completed a Series A financing of \$50M in Dec 2021.

Presenter: Clarissa Desjardins, PhD, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Connect Biopharma Holdings Limited

(NASDAQ:CNTB)

(In-Person)

Categorical Listings: Dermatology, Drug Discovery, Gene-Cell Therapy

Location: San Diego, California United States

Year Established: 2017 **Website:** www.connectbiopharm.com

Corporate Partners: In discussions with partners for lead candidate CBP-201 and CPB-307 for ulcerative colitis.

Funds Raised: \$220M in March 2021 IPO after a \$115M Series C round.

Presenter: Steven Chan, CFO

CoreTissue BioEngineering Inc.

(In-Person)

Categorical Listings: Cardiovascular, Other

Location: Yokohama, Japan

Year Established: 2016 **Website:** www.coretissue.com/english

Corporate Partners: The company partners with Teijin Pharma for mass production of ACL ligament.

Funds Raised: The company plans to raise \$10M as Series B in 2023, \$15M as Series C in 2025.

Presenter: Chiaki Takeda Waki, MBA, CEO

Corstasis Therapeutics

(In-Person)

TOC

Categorical Listings: Cardiovascular, Pulmonary, Renal

Location: Henderson, Nevada United States

Year Established: 2018 **Website:** www.corstasis.com

Corporate Partners: Program leverages the expertise of top tier CDMOs and CROs.

Funds Raised: \$11.5M to date through two rounds of investment.

Presenter: Benjamin (Ben) Esque, Founder & CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Createrna Science & Technology

(In-Person)

Categorical Listings: Autoimmune, Cardiovascular, Inflammation

Location: Wuhan, Hubei, China

Year Established: 2017 **Website:** www.createrna.com

Corporate Partners: QR Pharmaceutical

Funds Raised: \$150M invested by its Founders.

Presenter: Yaning Wang, PhD, CEO

Curate Biosciences

(In-Person)

Categorical Listings: Biomanufacturing, Gene-Cell Therapy, Immuno-oncology

Location: Carlsbad, California United States

Year Established: 2002 **Website:** www.curatebio.com

Corporate Partners: Throughout 2022, the company conducted early access programs with select biopharmas, CDMOs, systems suppliers, and academic/government organizations. Curate Biosciences has longstanding development relationships with Princeton & University of Maryland.

Funds Raised: \$45M venture/strategic funding since 2020, plus previous Angel and extensive non-dilutive funding.

Presenter: Jason Walsh, MBA, CFO

Curesponse Ltd.

(In-Person)

TOC

Categorical Listings: Artificial Intelligence (AI), Big Data, Bioinformatics

Location: Rehovot, Israel

Year Established: 2018 **Website:** www.curesponse.com

Corporate Partners: The technology has been developed with the Weizmann Institute of Sciences in Israel. Executing with Imperial College in London a multi-center clinical program.

Funds Raised: INP

Presenter: Guy Neev, MBA, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Curi Bio, Inc.

(In-Person)

Categorical Listings: Cardiovascular, Drug Discovery, Gene-Cell Therapy

Location: Seattle, Washington United States

Year Established: 2015 **Website:** www.curibio.com

Corporate Partners: INP

Funds Raised: \$10M oversubscribed Series A closed end of year 2021.

Presenter: Elliot Fisher, Co-Founder & CBO

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)(In-Person)

Categorical Listings: Hematology, Oncology

Location: Berkeley Heights, New Jersey United States

Year Established: 1996 **Website:** www.cyclacel.com

Corporate Partners: Not disclosed

Funds Raised: INP

Presenter: Spiro Rombotis, MBA, MPH, President & CEO

Cytonus Therapeutics

Categorical Listings: Artificial Intelligence (AI), Big Data, Drug Delivery

Location: Carlsbad, California United States

Year Established: 2018 **Website:** www.cytonus.com

Corporate Partners: Two confidential pilot projects underway.

Funds Raised: INP

Presenter: Remo Moomiaie-Qajar, MD, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Deka Biosciences, Inc

Categorical Listings: Hematology, Immunology, Inflammation

Location: Germantown, Maryland United States

Year Established: 2018 **Website:** www.dekabiosciences.com

Corporate Partners: Seeking corporate partners.

Funds Raised: \$20M Series A round in November 2021, followed by another \$20M at the end of 2023.

Presenter: John Mumm, PhD, CEO

(In-Person)

Desentum Oy

Categorical Listings: Antibodies, Immunology, Inflammation

Location: Helsinki, Finland

Year Established: 2011 **Website:** www.desentum.fi

Corporate Partners: No corporate partners at this point.

Funds Raised: More than €24M, €18M in equity and €6M in grants / government loans.

Presenter: Pekka Mattila, MSc, CEO

(In-Person)

DNA Analytics

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Diagnostics, Drug Discovery

Location: Greenbelt, Maryland United States

Year Established: 2015 **Website:** www.dnaanalytics.com

Corporate Partners: None

Funds Raised: \$5M from federal, state, local, and private sources. At this time, networking for clients.

Presenter: Raymond Peterson, PhD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Ellipses Pharma Ltd

(In-Person)

Categorical Listings: Oncology

Location: London, United Kingdom

Year Established: 2015 **Website:** www.ellipses.life

Corporate Partners: Ellipses acquires assets from a range of public companies, private companies, research organisations and academic institutions and then commits to their clinical development.

Funds Raised: \$120M as ordinary share capital.

Presenter: Rajan Jethwa, MD, CEO

Elpiscience Biopharma

(In-Person)

Categorical Listings: Antibodies, Immuno-oncology, Oncology

Location: Shanghai, China

Year Established: 2017 **Website:** www.elpiscience.com

Corporate Partners: Elpiscience has 2 innovative molecules partnered with Inhibrx.

Elpiscience has entered an exclusive licensing agreement with Compass. Elpiscience has established a clinical collaboration with Junshi.

Funds Raised: Approximately \$251M to date.

Presenter: Darren Ji, MD, PhD, MBA, CEO

EMPIRI, Inc.

(In-Person)

Categorical Listings: Diagnostics, Drug Discovery, Oncology**Location:** Houston, Texas United States**Year Established:** 2018 **Website:** www.empiricancer.com**Corporate Partners:** Observational clinical trial is in collaboration with MD Anderson and Houston Methodist Research Institute (HMRI). The company has oncologists at MD Anderson, HMRI, and Baylor College of Medicine ready for a second.**Funds Raised:** \$250K founders, \$500K Angel, \$1.15M grant, \$200K service revenue. Service revenue is increasing.**Presenter:** Kyuson Yun, PhD, Co-Founder

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Emyria Limited (ASX:EMD)

(In-Person)

Categorical Listings: Big Data, CNS-Neurological, Drug Discovery**Location:** Leederville, Australia**Year Established:** 2018 **Website:** www.emyria.com**Corporate Partners:** Developing MDMA library with the University of Western Australia.**Funds Raised:** ~\$20M to date.**Presenter:** Michael Winlo, MD, MBA, CEO**ENHANC3D GENOMICS**

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Diagnostics**Location:** Cambridge, United Kingdom**Year Established:** 2020 **Website:** www.enhanc3dgenomics.com**Corporate Partners:** The company was awarded an immunology J&J QuickFire Challenge and has secured a commercial pilot contract with a major CDMO.**Funds Raised:** £1.75M in March 2021, £10M in August 2022.**Presenter:** Debora Lucarelli, PhD, CEO

EnteroBiotix

(In-Person)

Categorical Listings: Gastrointestinal, Hepatic, Microbiome

Location: Bellshill, United Kingdom

Year Established: 2017 **Website:** www.enterobiotix.com

Corporate Partners: None at present.

Funds Raised: £28M to date, through Seed, Series A and the first tranche of Series B.

Presenter: James McIlroy, MD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Enveric Biosciences (NASDAQ:ENVB)

(In-Person)

Categorical Listings: CNS-Neurological

Location: Cambridge, Massachusetts United States

Year Established: 2020 **Website:** www.enveric.com

Corporate Partners: Hotchkiss Brain Institute

Funds Raised: Several rounds

Presenter: Bob Dagher, MD, CMO

Enzene Biosciences Ltd.

(In-Person)

Categorical Listings: Antibodies, Biomanufacturing, Biosimilars

Location: Pune, India

Year Established: 2006 **Website:** www.enze.com

Corporate Partners: The company partners with top Indian Pharma companies for biosimilars; it also works with MNCs and other small/mid biotech globally.

Funds Raised: Approximately \$110M+ funds to date.

Presenter: Himanshu Shashikant Gadgil, PhD, MS, CEO

Enzyme By Design, Inc.

(In-Person)

Categorical Listings: Biomanufacturing, Endocrine-Metabolic, Oncology

Location: Chicago, Illinois United States

Year Established: 2015 **Website:** www.enzymebydesign.com

Corporate Partners: Enzyme By Design is talking to major pharma players regarding both its asparaginase asset and its TRAIL asset (separately).

Funds Raised: EBD has been awarded multiple small business grants by the NIH totalling \$3.5M.

Presenter: Jon Weston, MBA, CFO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

EpiAxis Therapeutics

(In-Person)

Categorical Listings: Epigenetic, Immuno-oncology, Oncology

Location: Sydney, Australia

Year Established: 2015 **Website:** www.epiaxistherapeutics.com

Corporate Partners: EpiAxis has collaborations with Seattle Children's Hospital; Icahn School of Medicine at Mount Sinai; and with University Hospital Network (Princess Margaret Cancer Centre).

Funds Raised: \$4.6M to date

Presenter: Jeremy Chrisp, PhD, CEO

Expres2ion Biotech Holding AB (OtherSTO:EXPRS2)

(In-Person)

Categorical Listings: Infectious Disease, Oncology, Vaccines

Location: Hoersholm, Denmark

Year Established: 2010 **Website:** www.expres2ionbio.com

Corporate Partners: The company's COVID-19 vaccine is out-licensed to Bavarian Nordic which is currently running the Phase III trial.

Funds Raised: More than \$35M, with more than \$7M in 2022.

Presenter: Bent U. Frandsen, MSc, CEO

First Ascent Biomedical

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Bioinformatics, Contract Drug Development

Location: Beaverton, Oregon United States

Year Established: 2016 **Website:** www.firstascentbio.com

Corporate Partners: Technology has been validated and results jointly published with Stanford, Johns Hopkins, FIU, etc. The company has worked and generated revenue from pharmaceutical partners: Roche, Galera, GSK, Prelude, Champions Oncology.

Funds Raised: Oversubscribed Angel round: \$600K. The platform has been built and validated from \$3.2M of NSF/NIH non-dilutive grants.

Presenter: Jim Jerome Foote, MBA, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

FloraWorks

(In-Person)

Categorical Listings: Drug Discovery

Location: Portland, Oregon United States

Year Established: 2020 **Website:** www.flora-works.com

Corporate Partners: INP

Funds Raised: \$4.5M to date

Presenter: Alleh Lindquist, CEO

Fzata, Inc.

(In-Person)

Categorical Listings: Antibodies, Drug Delivery, Gastrointestinal

Location: Halethorpe, Maryland United States

Year Established: 2015 **Website:** www.fzata.com

Corporate Partners: The company is in diligence, moving to term sheet, with two potential corporate partners: one is interested in the infectious disease candidate and the other in IBD.

Funds Raised: \$500K Founders. \$500K VC investment in 2016 and \$500K in 2017. \$17M in non-dilutive funding from the NIH.

Presenter: Elizabeth Anne Smith, PhD, MBA, CBO

G+FLAS Life Sciences, Inc.

(In-Person)

Categorical Listings: Antibodies, Biomanufacturing, Biosimilars

Location: Cheongju, South Korea

Year Established: 2014 **Website:** www.gflas.com

Corporate Partners: Under negotiation.

Funds Raised: \$40M to date since 2016.

Presenter: Sunghwa Choe, PhD, MS, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

GEn1E Lifesciences Inc.

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Autoimmune, Bioinformatics

Location: Palo Alto, California United States

Year Established: 2018 **Website:** www.gen1e.com

Corporate Partners: The company is Phase 2 ready, having successfully completed SAD/MAD Phase 1 study in 48 people. Would love to have strategic partnerships with companies who can benefit from this advancement.

Funds Raised: Only Seed capital and have spent less than \$10M to date from early discovery to Phase 2.

Presenter: Ritu Lal, PhD, MS, CEO

GeoVax Labs, Inc. (NASDAQ:GOVX)

(In-Person)

Categorical Listings: Immuno-oncology, Vaccines

Location: Smyrna, Georgia United States

Year Established: 2001 **Website:** www.geovax.com

Corporate Partners: COVID-19 and Immuno-oncology programs are internally funded. Infectious disease programs for hemorrhagic fever and Zika viruses have been funded through NIAID and the U.S. Army. Open to partnering discussions.

Funds Raised: \$67M since uplisting to NASDAQ in 2020.

Presenter: David Dodd, MS, Chairman & CEO

Gilboa Therapeutics, Inc.

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Oncology

Location: Rehovot, Israel

Year Established: 2021 **Website:** www.gilboa.bio

Corporate Partners: In progress

Funds Raised: Approximately \$4.5M to date.

Presenter: Noam Pilpel, PhD, MSc, CTO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

HEALIOS K.K. (TSE:4593)

Categorical Listings: CNS-Neurological, Gene-Cell Therapy, Hepatic

Location: Tokyo, Japan

Year Established: 2011 **Website:** www.healios.co.jp/en

Corporate Partners: License from Athersys for the development, sale and manufacturing of Multistem for ischemic stroke and ARDS in Japan. Joint development with Sumitomo Pharma for iPSC-derived RPE cells for AMD.

Funds Raised: The total net proceeds from the International Offering were approximately \$60.6M in 2021. (111.92 yen/US dollar).

Presenter: Richard P Kincaid, Executive Officer & CFO

(In-Person)

Healis Therapeutics, Inc

Categorical Listings: CNS-Neurological, Dermatology

Location: Newport Beach, California United States

Year Established: 2021 **Website:** www.healistera.com

Corporate Partners: INP

Funds Raised: Seed funding to date.

Presenter: Eric Finzi, MD, PhD, Co-Founder & CEO

(In-Person)

Herantis Pharma Plc (OMXH:HRTIS)

(Virtual)

Categorical Listings: CNS-Neurological, Neurology**Location:** Espoo, Finland**Year Established:** 2008 **Website:** www.herantis.com**Corporate Partners:** Herantis' strategy is to pursue partnering opportunities for clinical development and commercialization of its assets.**Funds Raised:** €75M**Presenter:** Antti Vuolanto, PhD, CEO**Hoba Therapeutics**

(In-Person)

Categorical Listings: CNS-Neurological, Neuropathy**Location:** Copenhagen N, Denmark**Year Established:** 2016 **Website:** www.hobatherapeutics.com**Corporate Partners:** Corporate partners to be disclosed under CDA.**Funds Raised:** €5M in equity + €5M in grants.**Presenter:** Mikkel Dybkjaer, MS, CFO**Hyloris Pharmaceuticals SA** (Euronext:HYL)

(In-Person)

Categorical Listings: Cardiovascular, Other, Women's Health**Location:** Liège, Belgium**Year Established:** 2012 **Website:** www.hyloris.com**Corporate Partners:** AFT Pharma for the commercialization of Maxigesic® and AltaThera for the commercialization of Sotalol IV**Funds Raised:** €62M at IPO (June 2020), €15M equity raise in March 2022.**Presenter:** Stijn Van Rompay, MS, Co-Founder & CEO

ID4Pharma

(In-Person)

Categorical Listings: Drug Discovery, Hematology, Immuno-oncology

Location: Pittsburgh, Pennsylvania United States

Year Established: 2015 **Website:** www.ID4Pharma.com

Corporate Partners: ID4 is seeking strategic partners with VCs and Pharma.

Funds Raised: \$2.3M SBIR Fast Track grant was awarded to ID4Pharma for FDA IND studies.

Presenter: Xiangqun (Sean) Xie, MD, PhD, EMBA, Founder & Chairman of the Board

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

ILIAS Biologics Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Drug Delivery, Fibrosis

Location: Daejeon, South Korea

Year Established: 2015 **Website:** www.iliasbio.com

Corporate Partners: Vaccine pipeline is being developed in partnership with HK inno.N. Cancer pipeline is being developed in partnership with JW Pharmaceutical.

Funds Raised: More than \$40M since 2016.

Presenter: Taejin (Justin) Ham, MSc, MBA, CEO

ImaginAb Inc

(In-Person)

Categorical Listings: Antibodies, Immuno-oncology, Oncology

Location: Inglewood, California United States

Year Established: 2007 **Website:** www.imaginab.com

Corporate Partners: >19 deals with Pharma and Biotech companies to access CD8 ImmunoPET agent including, Pfizer, Bayer, AZ, Merck, Roche, BI.

Funds Raised: INP

Presenter: Ian Andrew Wilson, CEO

Immodulon Therapeutics Ltd

(In-Person)

Categorical Listings: Immunology, Oncology, Orphan-Rare Disease

Location: Middlesex, United Kingdom

Year Established: 2007 **Website:** www.immodulon.com

Corporate Partners: Undisclosed

Funds Raised: £50M (\$60M)

Presenter: Celia Habita, PhD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Immunis, Inc.

(In-Person)

Categorical Listings: Autoimmune, Drug Discovery, Gene-Cell Therapy

Location: Irvine, California United States

Year Established: 2020 **Website:** www.immunisbiomedical.com

Corporate Partners: Phase 1/2a will be conducted at the University of California Irvine's Medical Center, UCI Health, which is part of the California Institute of Regenerative Medicine's Alpha Stem Cell Clinic Network.

Funds Raised: Closed a \$10M Series A First Closing financing led by Remiges Ventures with participation by other healthcare investment firms.

Presenter: Hans Keirstead, PhD, Chairman

Immunomic Therapeutics, Inc.

(In-Person)

Categorical Listings: Dermatology, Immuno-oncology, Oncology

Location: Rockville, Maryland United States

Year Established: 2005 **Website:** www.immunomix.com

Corporate Partners: HLB, ZENOAQ, Charles River Laboratories, Lineage Cell Therapeutics

Funds Raised: INP

Presenter: Bill Hearl, PhD, CEO

Immunwork, Inc.

(In-Person)

TOC

Categorical Listings: Antibodies, Cardiovascular, Drug Delivery

Location: Taipei, Taiwan, China

Year Established: 2014 **Website:** www.immunwork.com

Corporate Partners: INP

Funds Raised: \$24M Series A in Q2 2021.

Presenter: Kun-Po Li, PhD, MSc, Manager, External Collaboration & Clinical Development

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

iN Therapeutics

(In-Person)

Categorical Listings: CNS-Neurological, Neurology, Platform Technology

Location: Gyeonggi-do, South Korea

Year Established: 2020 **Website:** www.intherapeutics.com/en

Corporate Partners: Daewoong Pharma (mother company).

Funds Raised: iNT successfully closed Series A round with \$40M.

Presenter: Chongdeok Park, MBA, MS, CEO

IN8bio (NASDAQ:INAB)

(In-Person)

Categorical Listings: Drug Discovery, Gene-Cell Therapy, Oncology

Location: New York, New York United States

Year Established: 2016 **Website:** www.in8bio.com

Corporate Partners: INP

Funds Raised: \$86.4M

Presenter: William (Will) Ho, MBA, CEO

Inhalon Biopharma, Inc.

(In-Person)

TOC

Categorical Listings: Antibodies, Immunology, Infectious Disease

Location: Morrisville, North Carolina United States

Year Established: 2018 **Website:** www.inhalon.com

Corporate Partners: Inhalon has partnered with Celltrion Inc. and the U.S. Army to advance its COVID-19 program.

Funds Raised: \$25M in equity, grants and awards.

Presenter: John Whelan, MBA, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

invIOs GmbH

(In-Person)

Categorical Listings: Drug Delivery, Immuno-oncology, Personalized Medicine

Location: Vienna, Austria

Year Established: 2021 **Website:** www.invios.com

Corporate Partners: The company is developing its programs independently.

Funds Raised: invIOs was demerged from APEIRON Biologics AG in 2022, and received Seed funding as part of the demerger.

Presenter: Peter Llewellyn-Davies, CEO

IONIQ Sciences

(In-Person)

Categorical Listings: Oncology, Personalized Medicine

Location: Salt Lake City, Utah United States

Year Established: 2004 **Website:** www.ioniqsciences.com

Corporate Partners: IONIQ has already conducted seven trials at premier cancer facilities across three continents.

Funds Raised: \$37M to date.

Presenter: Jared Bauer, MBA, CEO

iQure Pharma Inc.

(In-Person)

TOC

Categorical Listings: CNS-Neurological, Neurology, Neuropathy

Location: Princeton, New Jersey United States

Year Established: 2019 **Website:** www.iquirepharma.com

Corporate Partners: Open to collaboration, no current partners.

Funds Raised: \$900K to date with \$1.5M committed for the next round.

Presenter: Pawel (Paul) Zolnierczyk, MSc, ME, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Jaguar Health, Inc. (NASDAQ:JAGX)

(In-Person)

Categorical Listings: Gastrointestinal, Oncology, Orphan-Rare Disease

Location: San Francisco, California United States

Year Established: 2013 **Website:** www.jaguar.health

Corporate Partners: Knight Therapeutics: License for Mytesi (crofelemer) in Canada and Israel; SynWorld: License and services agreement for treatment of diarrhea in dogs in China with Jaguar's Canalevia (crofelemer) product.

Funds Raised: INP

Presenter: Lisa Conte, MS, MBA, Founder, President & CEO

Juno Diagnostics

(In-Person)

Categorical Listings: Diagnostics, Personalized Medicine, Reproductive Medicine

Location: San Diego, California United States

Year Established: 2021 **Website:** www.junodx.com

Corporate Partners: INP

Funds Raised: \$25M series A in May 2021.

Presenter: Amy N. Conrad, Investor Relations

KBio

Categorical Listings: Antibodies, Autoimmune, Biomanufacturing

Location: London, United Kingdom

Year Established: 2021 **Website:** www.kbio.com

Corporate Partners: NIAD

Funds Raised: INP

Presenter: Patrick James Doyle, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

KeifeRx LLC

Categorical Listings: CNS-Neurological, Drug Discovery

Location: McLean, Virginia United States

Year Established: 2019 **Website:** www.keiferx.com

Corporate Partners: The company's Alzheimer's program is being developed in partnership with Sun Pharma.

Funds Raised: \$7M in equity in an initial equity raise in August 2021.

Presenter: Chris Hoyt, CEO

(In-Person)

S-P

S-C

Kernal Bio

Categorical Listings: Fibrosis, Immuno-oncology, Infectious Disease

Location: Cambridge, Massachusetts United States

Year Established: 2016 **Website:** www.kernalbio.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Yusuf Erkul, MD, CEO

(In-Person)

Kintara Therapeutics, Inc. (NASDAQ:KTRA)

(In-Person)

TOC

Categorical Listings: Oncology**Location:** San Diego, California United States**Year Established:** 2007 **Website:** www.kintara.com**Corporate Partners:** No partners currently.**Funds Raised:** \$10M this year through two financings.**Presenter:** Robert Hoffman, President & CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

KORTUC Inc.

(In-Person)

Categorical Listings: Immuno-oncology, Oncology, Other**Location:** Tokyo, Japan**Year Established:** 2015 **Website:** kortuc.com**Corporate Partners:** INP**Funds Raised:** \$26M**Presenter:** Kazu Matsuda, MBA, CEO**Lassogen, Inc.**

(In-Person)

Categorical Listings: Drug Discovery, Oncology, Platform Technology**Location:** San Diego, California United States**Year Established:** 2019 **Website:** www.lassogen.com**Corporate Partners:** The company has been operating in semi-stealth mode and has yet to actively seek partnerships. Now ready to emerge and engage potential partners.**Funds Raised:** \$11M in Seed equity and notes to date.**Presenter:** Mark Burk, PhD, President & CEO

Latticon Antibody Therapeutics, Inc.

(In-Person)

Categorical Listings: Antibodies, Autoimmune, Cardiovascular

Location: Gaithersburg, Maryland United States

Year Established: 2021 **Website:** www.latticon.com

Corporate Partners: The company is seeking partners to co-develop its lead product "alpha-clash IL-2 immunocytokine".

Funds Raised: \$10M in 2021.

Presenter: John Li, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Lepu Biopharma Co., Ltd. (HKEX: 2157)

(In-Person)

Categorical Listings: Antibodies, Drug Discovery, Hematology

Location: Shanghai, China

Year Established: 2018 **Website:** en.lepubiopharma.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Hu Chaohong, PhD, Co-CEO

Levatio Therapeutics

(In-Person)

Categorical Listings: Autoimmune, Drug Discovery, Immunology

Location: San Diego, California United States

Year Established: 2021 **Website:** www.levatiotherapeutics.com

Corporate Partners: Neoantigen vaccines are being developed in partnership with ST Pharm for clinical trial.

Funds Raised: In 2021, \$3M was invested in Seed.

Presenter: Hyun-Bae Jie, PhD, MS, CEO

Lift BioSciences Ltd

(In-Person)

Categorical Listings: Contract Drug Development, Gene-Cell Therapy, Immuno-oncology

Location: London, United Kingdom

Year Established: 2016 **Website:** www.liftbiosciences.com

Corporate Partners: INP

Funds Raised: \$10M to date.

Presenter: Alex Blyth, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Lightship Inc.

(In-Person)

Categorical Listings: Cardiovascular, Contract Drug Development, Dermatology

Location: El Segundo, California United States

Year Established: 2018 **Website:** www.lightship.com

Corporate Partners: Lightship partners across the health ecosystem including top 10 pharmaceutical sponsors, biotechnology, digital health, healthcare systems, community engagement organizations, and technology partners to streamline the clinical development process.

Funds Raised: Over \$60M to date.

Presenter: David MacMurchy, CEO

Lipocine Inc. (NASDAQ:LPCN)

(In-Person)

Categorical Listings: CNS-Neurological, Drug Delivery, Endocrine-Metabolic

Location: Salt Lake City, Utah United States

Year Established: 1997 **Website:** www.lipocine.com

Corporate Partners: Lipocine's recently approved product, TLANDO, is partnered and commercialized through Halozyme, focused on new and proven therapeutic approaches with a market cap of ~ \$7B.

Funds Raised: More than \$100M to date through private/public offerings and product licensing.

Presenter: Mahesh Patel, PhD, President & CEO

List Biotherapeutics

Categorical Listings: Microbiome

Location: Indianapolis, Indiana United States

Year Established: 2022 **Website:** www.list-bio.com

Corporate Partners: List Labs and Genome & Co.

Funds Raised: \$48.4M in Series A1 and A2.

Presenter: Molly McGlaughlin, Chief Strategy Officer

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

LiveCare Corp

Categorical Listings: Artificial Intelligence (AI), Other, Platform Technology

Location: New York, New York United States

Year Established: 2017 **Website:** www.livecareusa.com

Corporate Partners: Samsung Next

Funds Raised: \$16.5M

Presenter: Peri Avitan, CEO

(In-Person)

Livivos Inc

Categorical Listings: Diagnostics, Fibrosis, Hepatic

Location: San Diego, California United States

Year Established: 2018 **Website:** www.livivos.com

Corporate Partners: Business conversations are underway with a medical device company in the same market segment.

Funds Raised: INP

Presenter: Pablo Prado, PhD, CEO

(In-Person)

Locate Bio Ltd

(In-Person)

TOC

Categorical Listings: Drug Delivery, Musculoskeletal, Regenerative Medicine

Location: Nottingham, United Kingdom

Year Established: 2014 **Website:** www.locatebio.com

Corporate Partners: Undisclosed partner

Funds Raised: £18.6M of equity investment and £2.6M of grant funding.

Presenter: John von Benecke, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Mabylon AG

(In-Person)

Categorical Listings: Antibodies, CNS-Neurological, Drug Discovery

Location: Schlieren, Switzerland

Year Established: 2015 **Website:** www.mabylon.com

Corporate Partners: Mabylon's neurodegenerative program on ALS/FTD is being developed in partnership with a US company.

Funds Raised: INP

Presenter: Niccolò Pengo, PhD, CSO

MAIA Biotechnology, Inc. (NYSE:MAIA)

(In-Person)

Categorical Listings: Immuno-oncology

Location: Chicago, Illinois United States

Year Established: 2018 **Website:** www.maiaibiotech.com

Corporate Partners: In February 2021, MAIA signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, which represents a significant cost-savings for the study.

Funds Raised: \$32M

Presenter: Vlad Vitoc, MD, MBA, CEO

MDimune Inc.

(In-Person)

Categorical Listings: Autoimmune, CNS-Neurological, Drug Delivery**Location:** Seoul, South Korea**Year Established:** 2015 **Website:** www.mdimmune.com**Corporate Partners:** R&D collaborations consist of the development of CDVs tailored to partners' need upon the research collaboration agreement and license agreement. Current collaboration partners are mainly Caravan (USA), NeoCura(China), ANU(Australia), NUS(Singapore) etc.**Funds Raised:** More than \$30M**Presenter:** Seung Wook Oh, PhD, CSO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Mediphage Bioceuticals, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Gene-Cell Therapy, Hematology**Location:** Toronto, Ontario Canada**Year Established:** 2016 **Website:** www.mediphage.ca**Corporate Partners:** INP**Funds Raised:** INP**Presenter:** Alvaro Amorrortu, MS, MBA, President & CEO**MedTherapy Biotechnology**

(In-Person)

Categorical Listings: Biomanufacturing, Contract Manufacturing, Gene-Cell Therapy**Location:** Quincy, Massachusetts United States**Year Established:** 2018 **Website:** www.medtherapybiotech.com**Corporate Partners:** Various, not public information**Funds Raised:** \$20M Series A, \$1.8M Seed round. Leasing partners at \$3M. Seeking an additional \$25M.**Presenter:** Bikash Verma, MD, DVM, CEO

MelliCell, Inc

(In-Person)

Categorical Listings: Drug Discovery, Endocrine-Metabolic, Platform Technology

Location: Newton, Massachusetts United States

Year Established: 2020 **Website:** www.mellicell.com

Corporate Partners: The company currently has two technology validation partnerships that are among the top 5 players in the metabolic space.

Funds Raised: Seed Round \$3M

Presenter: Prince Nnah, PharmD, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Mesoblast Limited (ASX:MSB)

(In-Person)

Categorical Listings: Gene-Cell Therapy, Inflammation

Location: New York, New York United States

Year Established: 2004 **Website:** www.mesoblast.com

Corporate Partners: Mesoblast has a range of partners including European and China partnerships for chronic lower back pain and heart failure.

Funds Raised: Mesoblast has raised money through the direct investor offerings and debt financing activities.

Presenter: Silviu Itescu, MD, CEO

Micronoma

(In-Person)

Categorical Listings: Diagnostics, Microbiome, Oncology

Location: San Diego, California United States

Year Established: 2019 **Website:** www.micronoma.com

Corporate Partners: The company is developing its platform in house and relies on external partners to reach regulatory bodies and insurance providers.

Funds Raised: \$17.5M since 2020.

Presenter: Sandrine Miller-Montgomery, PharmD, PhD, CEO

Microvascular Therapeutics

(In-Person)

Categorical Listings: Cardiovascular, Diagnostics, Gene-Cell Therapy

Location: Tucson, Arizona United States

Year Established: 2009 **Website:** www.mvtpharma.com

Corporate Partners: Cannot disclose.

Funds Raised: \$14.3M (in kind, capital, non-diluting funds).

Presenter: Emmanuelle (Emmie) J. Meuillet, PhD, CSO & COO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

miDiagnostics nv

(In-Person)

Categorical Listings: Diagnostics, Gene-Cell Therapy, Immuno-oncology

Location: Leuven, Belgium

Year Established: 2015 **Website:** www.midiagnostics.com

Corporate Partners: Cannot disclose corporate partners for now.

Funds Raised: €150M to date, of which €20M from the European Investment Bank to ramp up production lines.

Presenter: Katleen Verleysen, PhD, CEO

Minovia Therapeutics

(In-Person)

Categorical Listings: Gene-Cell Therapy, Hematology, Immunology

Location: Tirat HaCarmel, Israel

Year Established: 2011 **Website:** www.minoviatx.com

Corporate Partners: Ongoing collaboration with Astellas Pharma on an independent product.

Funds Raised: \$27M equity; \$20M Astellas down-payment + expected milestone payments + royalties.

Presenter: Natalie Yivgi-Ohana, PhD, CEO

Mitoimmune Therapeutics Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Inflammation, Mitochondrial Therapeutic

Location: Seoul, South Korea

Year Established: 2018 **Website:** www.mitoimmune.com

Corporate Partners: Now, actively looking for partners and under discussion with potential partners.

Funds Raised: \$11M in 2019 and \$25M in 2021.

Presenter: Young Mee Lee, MS, Senior Director, BD Department

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Modality.ai

(In-Person)

Categorical Listings: CNS-Neurological, Diagnostics, Neurology

Location: San Francisco, California United States

Year Established: 2018 **Website:** www.modality.ai

Corporate Partners: Subject to Non-Disclosure

Funds Raised: \$2.8M in Angel and Venture funding; \$2.2M NIH grant.

Presenter: David Suendermann-Oeft, PhD, CEO

MOLCURE Inc.

(In-Person)

Categorical Listings: Antibodies, Artificial Intelligence (AI), Big Data

Location: Kawasaki, Japan

Year Established: 2013 **Website:** www.molcure.com

Corporate Partners: Partnership with Twist Biosciences, Sysmex and Nippon Chemiphar.

Funds Raised: \$9M to date.

Presenter: Ryu Ogawa, PhD, CEO

Molecular Templates (NASDAQ:MTEM)

(In-Person)



Categorical Listings: Oncology

Location: Austin, Texas United States

Year Established: 2017 **Website:** www.mtem.com

Corporate Partners: Bristol

Funds Raised: INP

Presenter: Eric Poma, PhD, CEO & CSO



Monument Therapeutics Limited

(In-Person)

Categorical Listings: CNS-Neurological, Neurology, Personalized Medicine

Location: Macclesfield, United Kingdom

Year Established: 2019 **Website:** www.monumenttx.com

Corporate Partners: Partnerships in place with Cambridge Cognition for the provision of digital biomarkers, and with TRX Biosciences for the provision of lipid formulation technology.

Funds Raised: Since spin-out (2021), £3.3M, funding preclinical development and first Phase 1 study.

Presenter: Jenny Barnett, PhD, MA, CEO

Morphocell Technologies Inc.

(In-Person)

Categorical Listings: Gene-Cell Therapy, Hepatic, Regenerative Medicine

Location: Laval, Quebec Canada

Year Established: 2018 **Website:** www.morphocell.com

Corporate Partners: Confidential

Funds Raised: \$4M in Seed round, \$2M in non-diluting grants.

Presenter: Massimiliano (Max) Paganelli, MD, PhD, Co-Founder & CEO

N8 Medical

(In-Person)

Categorical Listings: Biosimilars, Cardiovascular, Dermatology

Location: Park City, Utah United States

Year Established: 2010 **Website:** www.n8medical.com

Corporate Partners: Under NDA.

Funds Raised: More than \$15M to date. An additional \$8M in non-dilutive financing.

Presenter: Carl Genberg, Chief Development & Scientific Officer

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Nanjing Novlead Biotechnology Co., Ltd. (In-Person)

Categorical Listings: Cardiovascular, Drug Delivery, Inflammation

Location: Nanjing, China

Year Established: 2018 **Website:** www.novlead.com

Corporate Partners: NO (nitric oxide) instant generation technology in cooperation with University of Michigan and many other research institutes.

Funds Raised: ¥30M in Series A funding in 2020; ¥120M in Series B in 2021.

Presenter: Wen Mao, PhD, Founder & CEO

NanoViricides, Inc. (NYSE:NNVC)

(In-Person)

Categorical Listings: Dermatology, Drug Delivery, Infectious Disease

Location: Shelton, Connecticut United States

Year Established: 2005 **Website:** www.nanoviricides.com

Corporate Partners: Seeking.

Funds Raised: More than \$125M since founding in 2005 in public equity-based financings.

Presenter: Anil R. Diwan, PhD, President & Executive Chairman

NB Health Laboratory Co., Ltd

(In-Person)

Categorical Listings: Antibodies, Autoimmune, Fibrosis

Location: Sapporo, Japan

Year Established: 2006 **Website:** www.nbhl.co.jp

Corporate Partners: ReCentrics Bio. (China), Shionogi (Japan), US-based animal health company (USA)

Funds Raised: \$7.5M April 2022.

Presenter: Kiyoshi Takayama, PhD, President

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Nectin Therapeutics

(In-Person)

Categorical Listings: Immuno-oncology

Location: Fort Lee, New Jersey United States

Year Established: 2018 **Website:** www.nectintx.com

Corporate Partners: MD Anderson Cancer Center

Funds Raised: Over \$25M in round A.

Presenter: Fabian Tenenbaum, MBA, CEO

Neo Auvra Corp.

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, CNS-Neurological

Location: Istanbul, Turkey

Year Established: 2021 **Website:** www.neoauvra.com

Corporate Partners: None so far, the company is looking for corporate partners.

Funds Raised: \$4.5M in the past 12 months as Seed investment.

Presenter: Tarcan Kiper, MSEE, CEO

NeoImmuneTech, Inc. (OtherKOSDAQ:950220) (In-Person)**Categorical Listings:** Immuno-oncology**Location:** Rockville, Maryland United States**Year Established:** 2014 **Website:** www.neoimmunetech.com**Corporate Partners:** Licensed NT-17 from Genexine. Clinical trial collaborations with Merck, Roche, BMS and Novartis.**Funds Raised:** Over \$100M**Presenter:** Daniel Rho, PhD, MBA, Director, Strategy and Planning

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

NetTargets Inc.

(Virtual)

Categorical Listings: Artificial Intelligence (AI), Bioinformatics, Drug Discovery**Location:** Daejeon, South Korea**Year Established:** 2019 **Website:** www.net-targets.com**Corporate Partners:** Over 10 partners (both public and private partners).**Funds Raised:** Total investment amount: \$5.62M (\$4.22M in 2021, \$1.4M in 2020).**Presenter:** Jongho Baek, PhD, CEO**Neuraly Inc.**

(In-Person)

Categorical Listings: CNS-Neurological**Location:** Gaithersburg, Maryland United States**Year Established:** 2016 **Website:** www.neuralymed.com**Corporate Partners:** Johns Hopkins**Funds Raised:** INP**Presenter:** Seulki Lee, PhD, CEO

Neuvivo, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Immunology, Inflammation

Location: Palo Alto, California United States

Year Established: 2019 **Website:** www.neuvivo.com

Corporate Partners: Currently, the company does not have corporate partners.

Funds Raised: INP

Presenter: Ari Azhir, PhD, CEO



Newomics Inc.

(In-Person)

Categorical Listings: Diagnostics, Personalized Medicine, Platform Technology

Location: Berkeley, California United States

Year Established: 2011 **Website:** www.newomics.com

Corporate Partners: Thermo Fisher, Bruker, Agilent, Waters, Shimadzu etc.

Funds Raised: Total: \$22M, with \$14M in non-dilutive NIH grants, and \$8M from Series A and Series B rounds..

Presenter: Daojing Wang, PhD, Founder & CEO

NIBEC Co., Ltd. (OtherKOSDAQ:138610)

(In-Person)

Categorical Listings: Cardiovascular, CNS-Neurological, Drug Delivery

Location: Seoul, South Korea

Year Established: 2004 **Website:** www.nibec.co.kr

Corporate Partners: Pulmonary fibrosis pipeline and drug delivery platform have been discussed with several pharmaceutical companies (not disclosed).

Funds Raised: INP

Presenter: Yoon Jeong Park, PhD, CTO

NOTA Laboratories Inc.

(In-Person)

Categorical Listings: Cardiovascular, Drug Delivery, Infectious Disease

Location: Ann Arbor, Michigan United States

Year Established: 2014 **Website:** www.notalabs.com

Corporate Partners: NOTA is developing its platform technologies in collaboration with NGK Spark Plugs Medical Division.

Funds Raised: More than \$8.5M with \$2.5M in June 2022.

Presenter: Malcolm Kahn, MBA, President & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Novellia

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Bioinformatics

Location: San Francisco, California United States

Year Established: 2022 **Website:** www.novellia.com

Corporate Partners: Top global multinational pharma cos, confidential (cannot disclose publicly at this time).

Funds Raised: INP

Presenter: Shashi Shankar, MBA, MPH, CEO

Nuevoco Pte. Ltd.

(In-Person)

Categorical Listings: Cardiovascular, Gene-Cell Therapy, Orphan-Rare Disease

Location: Singapore

Year Established: 2021 **Website:** www.nuevoco.com

Corporate Partners: INP

Funds Raised: \$24M in Series A funding.

Presenter: Yann Chong Tan, PhD, CEO

Nutshell Therapeutics

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Immunology, Immuno-oncology

Location: Shrewsbury, Massachusetts United States

Year Established: 2012 **Website:** www.allonutshell.cn

Corporate Partners: Two partners, one is a pharma and the other one, a biotech, for a combined 5 molecular targets for discovery and development of allosteric small molecules ongoing.

Funds Raised: \$75M Series A by March, 2022.

Presenter: Kevin Xie, PhD, MS, EVP

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

NuvOx Pharma

(In-Person)

Categorical Listings: Cardiovascular, CNS-Neurological, Immuno-oncology

Location: Tucson, Arizona United States

Year Established: 2008 **Website:** www.nuvoxpharma.com

Corporate Partners: Partnered with IAG and Statistical Revelations to help run Phase IIb/III trial in glioblastoma. Funding from NCI, NINDS and DOD.

Funds Raised: \$10.4 Series A. >\$5M in-kind. > \$11M in grants (NIH and DOD).

Presenter: Evan Unger, MD, President & CEO

Ochre Bio

(In-Person)

Categorical Listings: Drug Discovery, Endocrine-Metabolic, Fibrosis

Location: Oxford, United Kingdom

Year Established: 2019 **Website:** www.ochre-bio.com

Corporate Partners: NYU BioLabs

Funds Raised: \$30M Series A.

Presenter: Quin Wills, MD, PhD, Co-Founder & CSO

OKYO Pharma, Limited (NASDAQ:OKYO)

(In-Person)

TOC

Categorical Listings: Autoimmune, Immunology, Inflammation**Location:** New York, New York United States**Year Established:** 2018 **Website:** www.okyopharma.com**Corporate Partners:** OKYO has partnered with Ora Inc, a world-class ophthalmology contract research organization to guide the product development and lead the regulatory strategy of OK-101 for the treatment of dry eye.**Funds Raised:** Up to \$17M to date.**Presenter:** Gary S. Jacob, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Omniscope Limited

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Autoimmune, Big Data**Location:** Barcelona, Spain**Year Established:** 2021 **Website:** www.omniscope.ai**Corporate Partners:** Partner to €7M HORIZON EPIVINF project, funded by the European Union, which aims to gain an understanding of how viral infections (HIV/COVID) alter epigenetic regulation of host factors.**Funds Raised:** €2.5M Non-dilutive funding: European Commission (May'22) and Malta Enterprise (May'21). €1.3M SAFE Note: Friends & Family (Oct'21). \$10M Series A (Q1'2023)**Presenter:** Vijay Vaswani, MBA, MPH, Co-Founder & CEO**OncoPep, Inc.**

(In-Person)

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Orphan-Rare Disease**Location:** Cambridge, Massachusetts United States**Year Established:** 2010 **Website:** www.oncopep.com**Corporate Partners:** Clinical trials for the company's core cancer vaccine have been conducted in collaboration with global leading companies – Merck, AstraZeneca, and BMS.**Funds Raised:** \$32M to date with \$11M in 2021.**Presenter:** Jaehan Park, Chief Strategy Officer

Opus Genetics

(In-Person)

Categorical Listings: Gene-Cell Therapy, Ophthalmic, Orphan-Rare Disease

Location: Durham, North Carolina United States

Year Established: 2021 **Website:** www.opusgtx.com

Corporate Partners: None

Funds Raised: \$19M in the Seed round and progressing towards next round of funding.

Presenter: Benjamin (Ben) Yerxa, PhD, President & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Ordaos Bio

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Drug Discovery, Machine Learning

Location: New York, New York United States

Year Established: 2019 **Website:** www.ordaos.bio

Corporate Partners: Ordaos has announced a research collaboration with NonExomics focusing on three novel targets. Further partnerships are currently in stealth, with more in negotiation.

Funds Raised: \$5M Seed round closed in June 2022, round led by Middleland Capital.

Presenter: David Longo, MS, CEO

Orizuru Therapeutics, Inc.

(In-Person)

Categorical Listings: Cardiovascular, Endocrine-Metabolic, Gene-Cell Therapy

Location: Fujisawa, Kanagawa, Japan

Year Established: 2021 **Website:** www.orizuru-therapeutics.com/en

Corporate Partners: Large scale manufacturing and product formulation are developed in partnership with leading specialized companies in the fields.

Funds Raised: \$50M in 2021.

Presenter: Shinji Ogawa, PhD, VP & COO

OROX BioSciences, Inc.

Categorical Listings: Drug Discovery, Fibrosis, Hepatic

Location: San Diego, California United States

Year Established: 2017 **Website:** www.oroxbios.com

Corporate Partners: Work in progress

Funds Raised: INP

Presenter: Mehran F. Moghaddam, PhD, MBA, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Osmol Therapeutics, Inc.

Categorical Listings: Neuropathy, Oncology

Location: New Haven, Connecticut United States

Year Established: 2017 **Website:** www.osmoltherapeutics.com

Corporate Partners: None to date

Funds Raised: INP

Presenter: Bob Linke, MBA, President & CEO

(In-Person)

S-P

S-C

OYE Therapeutics Inc

Categorical Listings: CNS-Neurological, Neurology, Other

Location: Crown Point, Indiana United States

Year Established: 2019 **Website:** www.oyetherapeutics.com

Corporate Partners: Collaboration with Uniformed Services University, HJF Foundation for Advancement of Military Medicine, and the DoD.

Funds Raised: INP

Presenter: Brett Dines, MBA, Founder & CEO

(In-Person)

Pacylex Pharmaceuticals, Inc.

(In-Person)

Categorical Listings: Autoimmune, Immunology, Oncology

Location: Edmonton, Alberta Canada

Year Established: 2012 **Website:** www.pacylex.com

Corporate Partners: Partnered with Davos Pharma for CMC and regulatory support, Osmosis and Paraxel as CROs.

Funds Raised: CAD \$17M, Series A closed May 2021, CAD ~\$12.5M in non-dilutive grants.

Presenter: Michael Weickert, PhD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Panavance Therapeutics Inc.

(In-Person)

Categorical Listings: Oncology

Location: Berwyn, Pennsylvania United States

Year Established: 2021 **Website:** www.panavance.com

Corporate Partners: None. Open to strategic partnerships.

Funds Raised: INP

Presenter: Greg Bosch, MBA, CEO

Pan Cancer T B.V.

(In-Person)

Categorical Listings: Drug Discovery, Gene-Cell Therapy, Immunology

Location: Rotterdam, Netherlands

Year Established: 2020 **Website:** www.pancancer-t.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Katrien Reynders-Frederix, MBA, MS, CEO

Pano Therapeutics, Inc.

(In-Person)

Categorical Listings: Endocrine-Metabolic, Fibrosis, Mitochondrial Therapeutic

Location: San Francisco, California United States

Year Established: 2019 **Website:** www.panotherapeutics.com

Corporate Partners: INP

Funds Raised: \$10M in Founder funding and non-dilutive funding.

Presenter: Benjamin (Ben) Gibson, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Phaim Pharma

(In-Person)

Categorical Listings: Autoimmune, Dermatology, Endocrine-Metabolic

Location: London, United Kingdom

Year Established: 2015 **Website:** www.phaim.co.uk

Corporate Partners: nil

Funds Raised: Just under £2.5M.

Presenter: Nara Daubeney, MD, PhD, COO

Phanes Therapeutics, Inc.

(In-Person)

Categorical Listings: Antibodies, Immuno-oncology, Oncology

Location: San Diego, California United States

Year Established: 2016 **Website:** www.phanesthera.com

Corporate Partners: The company has partnered with various companies that utilize its novel antibodies for cell therapy and ADCs.

Funds Raised: INP

Presenter: Ming Wang, PhD, MBA, CEO

PharmCADD

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Drug Delivery, Drug Discovery

Location: Busan, South Korea

Year Established: 2019 **Website:** www.pharmacadd.com

Corporate Partners: Partnerships with domestic major pharmaceutical companies and currently drafting contract with US-based biotechnology company.

Funds Raised: \$20M in 2021. Currently in the process of seeking financial contribution from VC.

Presenter: ByoungYong (By) Lee, Executive Director

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Phoenix Molecular Designs Ltd.

(In-Person)

Categorical Listings: Diagnostics, Drug Discovery, Oncology

Location: Vancouver, British Columbia Canada

Year Established: 2012 **Website:** www.phoenixmd.ca

Corporate Partners: The company partnered with Roche to develop companion diagnostics for RSK2 which is now ready for prospective enrolment.

Funds Raised: Series A of \$20M and currently seeking a Series A2 for \$35M.

Presenter: Sandi Dunn, PhD, CEO

PhotonPharma Inc

(Virtual)

Categorical Listings: Immunology, Immuno-oncology, Oncology

Location: Fort Collins, Colorado United States

Year Established: 2018 **Website:** www.photonpharmaceuticals.com

Corporate Partners: TerumoBCT who will supply the device, disposables and FDA DMF to support manufacture of the Innocell product for clinical development.

Funds Raised: Approximately \$5.5M

Presenter: Terry Opgenorth, PhD, CEO

Pimera Therapeutics

Categorical Listings: Oncology

Location: San Diego, California United States

Year Established: 2016 **Website:** www.pimeratx.com

Corporate Partners: None to date, seeking partnerships for PMR-116.

Funds Raised: Raised \$10M from Seeds and Series A.

Presenter: Mustapha (Mus) Haddach, PhD, President & CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Prazer Therapeutics

Categorical Listings: CNS-Neurological, Drug Discovery, Neurology

Location: Seoul, South Korea

Year Established: 2019 **Website:** www.prazertx.com

Corporate Partners: Because of CDA, the company can't disclose now.

Funds Raised: More than \$143M until 2020. \$2.5M in grants since 2019.

Presenter: Kyung-Soo Inn, PhD, CEO

(In-Person)

PreciPoint GmbH

Categorical Listings: Big Data, Diagnostics, Hematology

Location: Freising, Germany

Year Established: 2018 **Website:** www.precipoint.de

Corporate Partners: Distribution partnership with Nikon.

Funds Raised: €20M

Presenter: Nicolas Weiss, CEO

(In-Person)

Prellis Biologics, Inc

Categorical Listings: Antibodies, Drug Discovery, Immunology

Location: Hayward, California United States

Year Established: 2016 **Website:** www.prellisbio.com

Corporate Partners: Sanofi and Bristol Myers Squibb

Funds Raised: INP

Presenter: Melanie Matheu, PhD, Chief Technology Officer

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Premas Biotech Pvt Ltd

Categorical Listings: Antibodies, Immuno-oncology, Oncology

Location: Gurgaon, India

Year Established: 2005 **Website:** www.premasbiotech.com

Corporate Partners: To be partnered.

Funds Raised: Invested about \$1M.

Presenter: Prabuddha Kundu, PhD, MSc, Co-Founder & Managing Director

(In-Person)

Presagen

Categorical Listings: Artificial Intelligence (AI), Machine Learning, Personalized Medicine

Location: San Francisco Bay Area, California United States

Year Established: 2016 **Website:** www.presagen.com

Corporate Partners: Global company FujiFilm Irvine Scientific is the global sole distributor of Presagen's first suite of products for the IVF sector, called Life Whisperer.

Funds Raised: Approx \$5M (Seed and post-Seed).

Presenter: Michelle Perugini, PhD, Co-Founder & CEO

(In-Person)

PRISM BioLab Co., Ltd.

(In-Person)

Categorical Listings: Drug Discovery, Fibrosis, Oncology**Location:** Fujisawa, Kanagawa, Japan**Year Established:** 2012 **Website:** www.prismbiolab.com**Corporate Partners:** Roche, Genentech, Boehringer Ingelheim, Merck KGaA, Servier, Eisai, Ohara**Funds Raised:** More than \$20M since 2016. In 2022, funding of \$10M and \$4M milestone.**Presenter:** Dai Takehara, MBA, President & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Processa Pharmaceuticals (NASDAQ:PCSA)

(In-Person)

Categorical Listings: Dermatology, Gastrointestinal, Oncology**Location:** Hanover, Maryland United States**Year Established:** 2018 **Website:** www.processapharmaceuticals.com**Corporate Partners:** None**Funds Raised:** INP**Presenter:** David Young, PharmD, PhD, CEO**Psilera Inc.**

(In-Person)

Categorical Listings: CNS-Neurological, Drug Discovery, Platform Technology**Location:** Tampa, Florida United States**Year Established:** 2019 **Website:** www.psilera.com**Corporate Partners:** Psilera has a deep network of leading industry, government, and academic partnerships.**Funds Raised:** INP**Presenter:** Chris Witowski, Co-Founder & CEO

Pyrojas Inc.

(In-Person)

Categorical Listings: Biomanufacturing, Gene-Cell Therapy, Immunology

Location: New York City, New York United States

Year Established: 2021 **Website:** INP

Corporate Partners: None yet

Funds Raised: INP

Presenter: Archis Bagati, PhD, MSc, Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

QBiotics Group Limited

(In-Person)

Categorical Listings: Dermatology, Drug Discovery, Oncology

Location: Brisbane, Australia

Year Established: 2004 **Website:** www.qbiotics.com

Corporate Partners: Lead product: Virbac, global animal health company; STELFONTA® marketing and distribution partner. Merck (USA), global pharmaceutical company: clinical collaboration for Phase 1/2 tigilanol tiglate and KEYTRUDA® combination in patients with advanced melanoma.

Funds Raised: More than AUD \$193M with AUD \$85M raised in 2021. AUD \$48M in government grants.

Presenter: Victoria Gordon, PhD, CEO & Managing Director

Qritive

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Diagnostics, Machine Learning

Location: Singapore

Year Established: 2017 **Website:** www.qritive.com

Corporate Partners: Tech companies: Dell, Philips, AWS; Device partners: Philips, Hamamatsu.

Funds Raised: INP

Presenter: Rahul Garg, MD, MBA, Chief Strategy Officer

QurCan Therapeutics Inc.

(In-Person)

Categorical Listings: Drug Delivery, Gene-Cell Therapy, Immuno-oncology

Location: Toronto, Ontario Canada

Year Established: 2018 **Website:** www.qurcan.com

Corporate Partners: RNA therapeutic pipeline is being developed in collaboration with undisclosed industry partners.

Funds Raised: \$2.5M Seed money in Q1-2021.

Presenter: John (Reid) Amini, PhD, MBA, EVP, Strategic Partnership & Business Development

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Quthero Inc

(In-Person)

Categorical Listings: Dermatology

Location: Miami, Florida United States

Year Established: 2017 **Website:** www.quthero.com

Corporate Partners: Multiple device companies and overseas pharma, some of whom wish to remain undisclosed.

Funds Raised: >\$1M in grants to support research, ~\$1.29M in equity and \$110K in non-dilutive financing to support hiring and company operations.

Presenter: Milica Radisic, PhD, Founder & CEO

Radiance Therapeutics, Inc.

(In-Person)

Categorical Listings: Drug Delivery, Ophthalmic

Location: Fremont, California United States

Year Established: 2018 **Website:** www.radiancetherapeutics.com

Corporate Partners: Radiance has partnered with a Fortune 500 company to supply devices and obtained an LOI for exclusive radiation supply and manufacturing.

Funds Raised: \$6.2M Series A in 2019. \$6.2M Convertible Note converts 30% discount to B round, \$20M cap.

Presenter: Laurence Marsteller, MD, MSc, CEO

Radiopharm Theranostics (ASX:RAD)

(In-Person)

Categorical Listings: Drug Delivery, Oncology

Location: Carlton, Australia

Year Established: 2021 **Website:** www.radiopharmtheranostics.com

Corporate Partners: One asset in co-development with Lantheus.

Funds Raised: AUD \$70M

Presenter: Riccardo Canevari, CEO



Rancho Santa Fe Bio, Inc.

(In-Person)

Categorical Listings: Cardiovascular, Musculoskeletal, Orphan-Rare Disease

Location: Rancho Santa Fe, California United States

Year Established: 2019 **Website:** www.rsfbio.com

Corporate Partners: Sanofi, Mayo Clinic and University of Minnesota Medical School

Funds Raised: \$2.5M of a \$5M convertible note.

Presenter: Randy Berholtz, MBA, CEO

Rapid Novor Inc.

(In-Person)

Categorical Listings: Antibodies, Bioinformatics, Diagnostics

Location: Kitchener, Ontario Canada

Year Established: 2015 **Website:** www.rapidnovor.com

Corporate Partners: Rapid Novor is a JLABS company.

Funds Raised: INP

Presenter: Iain Rogers, MBA, VP, Sales & Marketing

RareStone Group

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, CNS-Neurological

Location: Shanghai, China

Year Established: 2019 **Website:** www.rarestonegroup.com

Corporate Partners: WAKIX® is licensed from Bioprojet Pharma. Alkindi® and Efmody® are licensed from Diurnal Pharma.

Funds Raised: \$80M Series A financing in July 2020.

Presenter: Shawn Xiang, PhD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Regencor, Inc.

(In-Person)

Categorical Listings: Cardiovascular, Regenerative Medicine

Location: San Carlos, California United States

Year Established: 2011 **Website:** www.regencor.com

Corporate Partners: None currently.

Funds Raised: Awarded nearly \$12M in grant funding including \$4M from NIH and \$3.9M from California Institute of Regenerative Medicine.

Presenter: Sean Edwards, CEO

Regenosine, Inc

(In-Person)

Categorical Listings: Drug Delivery, Musculoskeletal, Regenerative Medicine

Location: Princeton, New Jersey United States

Year Established: 2018 **Website:** www.regenosine.com

Corporate Partners: Lead product is being co-developed for veterinary use in partnership with Vetosine and Stonehaven Incubate.

Funds Raised: \$3.7M in Seed (\$1.3M dilutive). Raising \$3-5M to supplement \$8M pending grant funding to complete Phase I trials.

Presenter: Siddhesh (Sid) R Angle, PhD, President & CEO

Reglagene, Inc.

(In-Person)

Categorical Listings: Inflammation, Oncology

Location: Tucson, Arizona United States

Year Established: 2016 **Website:** www.reglagene.com

Corporate Partners: The company's brain cancer pipeline is undergoing diligence with several pharmaceutical companies.

Funds Raised: Reglagene raised a \$1.5M Seed Round, a \$1.5M Convertible Note, the first tranche of Series A, and \$1M in grants.

Presenter: Richard Austin, PhD, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Relief Therapeutics Holding SA (SIX:RLF.SW)

(In-Person)

Categorical Listings: Dermatology, Endocrine-Metabolic, Pulmonary

Location: Geneva, Switzerland

Year Established: 2013 **Website:** www.relieftherapeutics.com

Corporate Partners: Acer Therapeutics and InveniAi

Funds Raised: Approximately \$182M

Presenter: Jack Weinstein, MBA, Treasure & CFO

Reunion Neuroscience Inc. (NASDAQ:REUN)

(In-Person)

Categorical Listings: CNS-Neurological, Drug Discovery

Location: Toronto, Ontario Canada

Year Established: 2022 **Website:** www.reunionneuro.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Greg Mayes, President & CEO

ReviR Therapeutics, Inc

(In-Person)

Categorical Listings: CNS-Neurological, Oncology, Orphan-Rare Disease

Location: Brisbane, California United States

Year Established: 2021 **Website:** www.revirtx.com

Corporate Partners: XtalPi to create an RNA small molecule drug discovery platform based on AI+DEL technology.

Funds Raised: \$21M in pre-A funding.

Presenter: Peng Yue, PhD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

RevolKa Ltd.

(In-Person)

Categorical Listings: Antibodies, Artificial Intelligence (AI), Autoimmune

Location: Tokyo, Japan

Year Established: 2021 **Website:** en.revolka.com

Corporate Partners: One of the company's rare disease products is partnered with Sumitomo Pharma.

Funds Raised: INP

Presenter: Norio Hamamatsu, PhD, Senior Director, Head of US Office

ROPHIBIO, INC.

(In-Person)

Categorical Listings: Biosimilars, Ophthalmic

Location: Cheongju-si, South Korea

Year Established: 2015 **Website:** www.rophibio.com

Corporate Partners: Amicogen, Inc. and Bifido Co., Ltd are both investors and strategic partners to Rophibio.

Funds Raised: More than \$5M from government grants. 2017: \$0.8M. 2018: \$0.6M. 2021: \$6M. 2022: \$4M (Dec 2022). Total about \$16.5M

Presenter: Sung Ho Hahm, PhD, CEO

Rubedo Life Sciences

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Dermatology, Inflammation

Location: Sunnyvale, California United States

Year Established: 2018 **Website:** www.rubedolife.com

Corporate Partners: INP

Funds Raised: \$33M between 1st close of its Series A and Seed round led by Khosla Ventures and Ahren Innovation Capital.

Presenter: Marco Quarta, PhD, Co-Founder & CEO



RUMI Scientific, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Orphan-Rare Disease, Renal

Location: New York, New York United States

Year Established: 2016 **Website:** www.rumiscientific.com

Corporate Partners: RUMI has a close collaboration with the Seaver Autism Center at the Icahn School of Medicine, NYC along with various foundations.

Funds Raised: INP

Presenter: Allen Fienberg, PhD, Chairman & CEO

SAB Biotherapeutics, Inc. (NASDAQ:SABS)

(In-Person)

Categorical Listings: Gastrointestinal, Immunology, Infectious Disease

Location: Sioux Falls, South Dakota United States

Year Established: 2014 **Website:** www.sab.bio

Corporate Partners: Emergent and others to be named in 2023.

Funds Raised: INP

Presenter: Alexandra Kropotova, MD, MBA, EVP & CMO

Safi Biotherapeutics

(In-Person)

Categorical Listings: Cardiovascular, Gene-Cell Therapy, Hematology

Location: Cambridge, Massachusetts United States

Year Established: 2019 **Website:** www.safi.bio

Corporate Partners: iBio, Inc., Massachusetts General Hospital, Sciperio Inc.,

Funds Raised: \$14M. (\$12.5M non-dilutive US DoD funding; \$1.5M private investment)

Presenter: Doug McConnell, MBA, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Samsara Therapeutics Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Neurology, Neuropathy

Location: Oxford, United Kingdom

Year Established: 2018 **Website:** www.samsaratherapeutics.com

Corporate Partners: Samsara's CMT1A discovery asset is being developed with support from CMTRF.

Funds Raised: \$22M

Presenter: Peter Hamley, PhD, MBA, CSO

SapiensBio Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Drug Discovery, Fibrosis

Location: Seongnam, South Korea

Year Established: 2018 **Website:** www.sapiensbio.com

Corporate Partners: SBC101 program under developed in partnership with YD Life Science Ltd. SBC107 program under developed in partnership with ALBORADA Drug Discovery Institute at University of Cambridge and YD Life Science Ltd.

Funds Raised: INP

Presenter: Jose Freire, PhD, CEO

SCM Lifescience (KRX:298060)

(In-Person)

Categorical Listings: Autoimmune, Dermatology, Gastrointestinal

Location: Incheon, South Korea

Year Established: 2014 **Website:** www.scmlifescience.com

Corporate Partners: Dermatology product has been developed with one partner, Handok Pharmaceuticals, in South Korea and another partner, Duopharma in Malaysia.

Funds Raised: \$20M in 2008, \$17M in 2014, \$39M in 2018 thru funding, the company was listed in KOSDAQ.

Presenter: Seokjo (Jo) Kim, PhD, MS, R&D Head

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Seal Rock Therapeutics, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Endocrine-Metabolic, Fibrosis

Location: Seattle, Washington United States

Year Established: 2016 **Website:** www.sealrocktx.com

Corporate Partners: In advanced partnering discussions for parenterally administered SRT-015 in acute liver disease. Multiple ongoing discussions with potential partners/acquirers for full pipeline or individual candidates.

Funds Raised: Over \$21M, with \$5.5M convertible notes, \$17.5M non-dilutive transaction revenue, and recent NIH-SBIR grant for SRT-015 in alcoholic hepatitis.

Presenter: Neil McDonnell, PharmD, CEO

Senex Biotechnology

(Virtual)

Categorical Listings: Cardiovascular, Oncology

Location: Columbia, South Carolina United States

Year Established: 2002 **Website:** www.senexbio.com

Corporate Partners: None

Funds Raised: \$3.4M in Seed and Series A investment. \$16M in NIH and Dept. of Defense grants.

Presenter: Dennis Goldberg, PhD, CEO

Sengenics Corporation, LLC

(In-Person)

Categorical Listings: Antibodies, Autoimmune, Bioinformatics

Location: Billerica, Massachusetts United States

Year Established: 2015 **Website:** www.sengenics.com

Corporate Partners: None

Funds Raised: INP

Presenter: Gerald (Jerry) Williamson, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Sen-Jam Pharmaceutical

(In-Person)

Categorical Listings: Cardiovascular, Endocrine-Metabolic, Gastrointestinal

Location: Huntington, New York United States

Year Established: 2017 **Website:** www.sen-jam.com

Corporate Partners: KVK-Tech pharmaceutical manufacturer, Duke University, Stony Brook University - Center for Biotechnology

Funds Raised: \$4M in Seed round.

Presenter: Jacqueline (Jackie) Iversen, RPh, MS, Chief Clinical Officer & Founder

SFA Therapeutics, Inc.

(In-Person)

Categorical Listings: Autoimmune, Dermatology, Fibrosis

Location: Jenkintown, Pennsylvania United States

Year Established: 2016 **Website:** www.sfatherapeutics.com

Corporate Partners: Dermatology pipeline is being developed in conjunction with Temple University, and NASH pipeline is being developed in conjunction with Einstein Hospital/Jefferson University.

Funds Raised: \$4M in Seed capital to-date.

Presenter: Ira Charles Spector, PhD, CEO

Shorla Oncology

Categorical Listings: Oncology

Location: Boston, Massachusetts United States

Year Established: 2018 *Website:* www.shorlaoncology.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Sharon Cunningham, MBA, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Simcere Inc (HKEX:2096)

Categorical Listings: Autoimmune, CNS-Neurological, Immuno-oncology

Location: Cambridge, Massachusetts United States

Year Established: 1995 *Website:* en.simcere.com

Corporate Partners: Currently 30 external alliances ongoing.

Funds Raised: Publicly traded

Presenter: Michael Bayewitch, PhD, Executive Director, International Business Development

(In-Person)

SIRPant Immunotherapeutics Inc.

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Oncology

Location: Hummelstown, Pennsylvania United States

Year Established: 2020 *Website:* www.sirpantimmunotx.com

Corporate Partners: INP

Funds Raised: More than \$27M

Presenter: Rita Bárcia, PhD, VP, Development & Operations

(In-Person)

Smart Dental Systems

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Diagnostics

Location: Moscow, Russian Federation

Year Established: 2019 **Website:** www.luxvita.clinic

Corporate Partners: No

Funds Raised: \$3.5M invested in 2019 to create infrastructure ANS clinic certification. \$0.5M for accreditation 2021-2022. IT example.

Presenter: Fatima Dzalaeva, DDS, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

SomaServe Limited

(In-Person)

Categorical Listings: CNS-Neurological, Drug Delivery, Gene-Cell Therapy

Location: Cambridge, United Kingdom

Year Established: 2018 **Website:** www.somaserve.com

Corporate Partners: Pharma collaborators currently undisclosed. 4 out of 7 partners are top 10 pharma.

Funds Raised: \$3.5M in Seed funding to date.

Presenter: Francesca Crawford, PhD, CEO

South Rampart Pharma

(In-Person)

Categorical Listings: Bioinformatics, CNS-Neurological, Drug Discovery

Location: New Orleans, Louisiana United States

Year Established: 2016 **Website:** www.southernrampartpharma.com

Corporate Partners: None

Funds Raised: Total : \$7.75M; Ochsner Health - \$4M (July 2019), \$1.85M (Sept 2021); \$1.9M NIH/NINDS STTR Fast-Track (2020 - 2023).

Presenter: Hernan Bazan, MD, CEO & Co-Founder

Spintellx Inc.

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Diagnostics

Location: Pittsburgh, Pennsylvania United States

Year Established: 2018 **Website:** www.spintellx.com

Corporate Partners: Inspirata, iCura, Rarecyte, CellNetix, Leica Microsystems, Genmab, Castle Biosciences

Funds Raised: A total of \$10.2M raised until Q4 2022 including \$7M non-dilutive funding from NIH and NSF.

Presenter: Dusty Majumdar, PhD, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Spiral Therapeutics, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Drug Delivery, Inflammation

Location: South San Francisco, California United States

Year Established: 2016 **Website:** www.spiraltx.com

Corporate Partners: Strategic collaboration (license out + investment) with large medtech player for otologic surgery.

Funds Raised: INP

Presenter: Hugo Peris, MS, CEO

SteroTherapeutics, LLC

(In-Person)

Categorical Listings: Hepatic, Oncology, Orphan-Rare Disease

Location: Doylestown, Pennsylvania United States

Year Established: 2017 **Website:** www.sterotx.com

Corporate Partners: The company's programs are partnered with the Moffitt Cancer Center, Dept. of VA Affairs, University of Texas.

Funds Raised: Less than \$20M

Presenter: Manohar Katakam, PhD, Founder & CEO

Sun Genomics

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Bioinformatics

Location: San Diego, California United States

Year Established: 2016 **Website:** www.sungenomics.com

Corporate Partners: Fonterra, NFL Teams, DSM Corporate,

Funds Raised: ~\$18M through 2022. Series B in-progress.

Presenter: Sunny Jain, MS, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Synaffix B.V.

(In-Person)

Categorical Listings: Antibodies, Immunology, Immuno-oncology

Location: Oss, Netherlands

Year Established: 2010 **Website:** www.synaffix.com

Corporate Partners: ADC Therapeutics, Mersana Therapeutics, Janssen (in collaboration with Mersana), Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin Co., Genmab, MacroGenics, Emergence Therapeutics

Funds Raised: Series A in 2014 (amount undisclosed).

Presenter: Anthony DeBoer, VP, Business Development

TargTex S.A.

(In-Person)

Categorical Listings: CNS-Neurological, Drug Delivery, Drug Discovery

Location: Torres Vedras, Portugal

Year Established: 2019 **Website:** www.targtex.com

Corporate Partners: No partnerships

Funds Raised: INP

Presenter: João Seixas, PhD, CEO

Tatara Therapeutics, Inc.

(In-Person)

Categorical Listings: Drug Delivery, Oncology, Personalized Medicine

Location: San Francisco, California United States

Year Established: 2018 **Website:** www.tatararx.com

Corporate Partners: INP

Funds Raised: \$3M to date, from Angel and Seed investors.

Presenter: Marguerite Hutchinson, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

T-Cypher Bio Ltd

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Bioinformatics, Drug Discovery

Location: Oxford, United Kingdom

Year Established: 2021 **Website:** www.tcypherbio.com

Corporate Partners: INP

Funds Raised: £7.8M; currently closing a funding round.

Presenter: Mark Lees, PhD, VP, Corporate Development

Tegmine Therapeutics, Inc.

(In-Person)

Categorical Listings: Antibodies, Bioinformatics, Drug Delivery

Location: South San Francisco, California United States

Year Established: 2017 **Website:** www.tegminetx.com

Corporate Partners: Collaboration deal to discover novel antibodies with Alloy Therapeutics.

Funds Raised: INP

Presenter: Jeffrey (Jeff) Bernstein, PhD, CEO

Think Bioscience

(In-Person)

TOC

Categorical Listings: Autoimmune, Cardiovascular, Drug Discovery

Location: Boulder, Colorado United States

Year Established: 2021 **Website:** www.thinkbioscience.com

Corporate Partners: INP

Funds Raised: \$20M+ to date including \$1.75M in non-dilutive grants.

Presenter: Philip Jeng, MBA, Co-Founder & COO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

ThinkingNode Life Science, Inc.

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Bioinformatics

Location: Rancho San Diego, California United States

Year Established: 2017 **Website:** www.thinkingnodelife.ai

Corporate Partners: Customers: J&J, Kyowa Kirin, Zentalis, Honda Research.

Funds Raised: INP

Presenter: Khai Pham, MD, PhD, Founder & CEO

Tiziana Life Sciences (NASDAQ:TLSA)

(In-Person)

Categorical Listings: Antibodies, Autoimmune, CNS-Neurological

Location: London, United Kingdom

Year Established: 2014 **Website:** www.tizianalifesciences.com

Corporate Partners: INP

Funds Raised: \$10M March 2020, \$57.2M August 2020.

Presenter: Matthew W. Davis, MD, RPh, CMO and acting CSO

Todos Medical Ltd. (OtherTOMDF:TOMDF)

(In-Person)

Categorical Listings: Diagnostics, Immunology**Location:** New York, New York United States**Year Established:** 2010 **Website:** www.todosmedical.com**Corporate Partners:** COVID-19 oral antiviral targeting 3CL protease is being developed through a partnership with NLC Pharma.**Funds Raised:** \$15M**Presenter:** Gerald Commissiong, President & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)

(In-Person)

Categorical Listings: CNS-Neurological, Immunology, Infectious Disease**Location:** Chatham, New Jersey United States**Year Established:** 2007 **Website:** www.tonixpharma.com**Corporate Partners:** INP**Funds Raised:** INP**Presenter:** Seth Lederman, MD, CEO**Travera, Inc.**

(In-Person)

Categorical Listings: Diagnostics, Oncology, Personalized Medicine**Location:** Medford, Massachusetts United States**Year Established:** 2018 **Website:** www.travera.com**Corporate Partners:** Travera is running clinical studies with NCI and multiple AMC partners, including DFCI, MGH, Mt. Sinai, Weill Cornell, Emory, and City of Hope.**Funds Raised:** \$13M Series A**Presenter:** Clifford Reid, PhD, CEO

Trevi Therapeutics, Inc. (NASDAQ:TRVI)

(In-Person)

TOC

Categorical Listings: CNS-Neurological, Fibrosis, Pulmonary**Location:** New Haven, Connecticut United States**Year Established:** 2011 **Website:** www.trevitherapeutics.com**Corporate Partners:** INP**Funds Raised:** INP**Presenter:** Jennifer Good, Co-Founder, President & CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Triplebar Bio

(In-Person)

Categorical Listings: Antibodies, Artificial Intelligence (AI), Autoimmune**Location:** Emeryville, California United States**Year Established:** 2019 **Website:** www.triplebar.com**Corporate Partners:** Undisclosed commercial partner**Funds Raised:** Undisclosed Seed funding**Presenter:** Maria Cho, MS, CEO**Tryp Therapeutics, Inc** (OTCQX:TRYPF)

(In-Person)

Categorical Listings: CNS-Neurological**Location:** Kelowna, British Columbia Canada**Year Established:** 2019 **Website:** www.trypterapeutics.com**Corporate Partners:** Clinical trials in partnership with University of Florida, University of Michigan; other high profile collaborations expected to be announced in the near term.**Funds Raised:** Approximately CAD \$12M at IPO in 2020 and subsequent financings.**Presenter:** Jim Gilligan, PhD, CEO

TwinStrand Biosciences, Inc.

(In-Person)

Categorical Listings: Bioinformatics, Diagnostics, Gene-Cell Therapy

Location: Seattle, Washington United States

Year Established: 2015 **Website:** www.twinstrandbio.com

Corporate Partners: Merck, Pfizer, GSK, AstraZeneca, Novartis, Foundation Medicine, DNAnexus, NIH, US National Marrow Donor Program, US National Toxicology Program, Health Canada.

Funds Raised: More than \$110M to date: >\$70M equity investment, >\$30M in product/service and licensing revenue, >\$10M in federal contracts and grants.

Presenter: Jesse Salk, MD, PhD, Founder & CSO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Valley Fever Solutions

(In-Person)

Categorical Listings: Infectious Disease, Orphan-Rare Disease

Location: Tucson, Arizona United States

Year Established: 2007 **Website:** www.valleyfeversolutions.com

Corporate Partners: The company is looking for the right partner to move to commercialization.

Funds Raised: \$23M: \$300K Founders, \$7M NIH, \$2M additional NIH, \$10M from technology donation, \$4M by University of Arizona.

Presenter: David Larwood, MS, MBA, CEO

Vasomune Therapeutics, Inc.

(In-Person)

Categorical Listings: Cardiovascular, Infectious Disease, Orphan-Rare Disease

Location: Toronto, Ontario Canada

Year Established: 2013 **Website:** www.vasomune.com

Corporate Partners: Co-development agreement with AnGes, Inc. (Japan).

Funds Raised: INP

Presenter: Douglas Hamilton, MBA, President & CEO

VC Cell Therapy

(In-Person)

TOC

Categorical Listings: Gene-Cell Therapy, Ophthalmic

Location: Kobe, Japan

Year Established: 2021 **Website:** www.vcct.jp/english

Corporate Partners: Collaborating with a top 10 ophthalmology pharma for RPE cell therapy development. Collaborating with Yasukawa electronic corporation for full-automation of cell manufacturing.

Funds Raised: \$8M as Seed in 2021, ~\$1M in grant per annum.

Presenter: Masayo Takahashi, MD, PhD, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

VerImmune Inc

(In-Person)

Categorical Listings: Drug Delivery, Immuno-oncology, Platform Technology

Location: Washington, D.C., United States

Year Established: 2020 **Website:** www.verimmune.com

Corporate Partners: (1) Research collaboration with Janssen Pharmaceuticals, (2) Exclusive license with Fosun Pharma for VerImmune's lead AIR-ViP product candidate, VERI-101 for the territory of China, Hong Kong and Macau.

Funds Raised: INP

Presenter: Joshua Wang, PhD, Founder & CEO

Vernagen, LLC

(In-Person)

Categorical Listings: Immunology, Infectious Disease, Vaccines

Location: Tucker, Georgia United States

Year Established: 2021 **Website:** www.vernagen.net

Corporate Partners: ST Pharm, Inc.

Funds Raised: \$3M for the initial stage development.

Presenter: Baek Kim, PhD, RPh, Founder & CEO

VESTECK, Inc.

Categorical Listings: Cardiovascular, Inflammation, Platform Technology

Location: West Chester, Pennsylvania United States

Year Established: 2019 **Website:** www.vesteck.com

Corporate Partners: Under NDA

Funds Raised: \$8.2M Series A preferred equity.

Presenter: Joseph (Joe) Rafferty, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Viewpoint Molecular Targeting

Categorical Listings: Oncology, Personalized Medicine

Location: Coralville, Iowa United States

Year Established: 2015 **Website:** www.viewpointmt.com

Corporate Partners: The company is a University of Iowa spinout with several major academic centers partnering with them on clinical trials.

Funds Raised: INP

Presenter: Thijs Spoor, MBA, CEO

(In-Person)

Visgenx, Inc.

Categorical Listings: Gene-Cell Therapy, Ophthalmic

Location: Santa Cruz, California United States

Year Established: 2018 **Website:** www.visgenx.com

Corporate Partners: No current partner.

Funds Raised: INP

Presenter: Martin (Marty) Emanuele, PhD, Co-Founder & CEO

(In-Person)

Watershed Therapeutics

(In-Person)

TOC

Categorical Listings: Drug Delivery, Infectious Disease, Women's Health

Location: Bellevue, Washington United States

Year Established: 2019 **Website:** www.watershedtx.com

Corporate Partners: INP

Funds Raised: \$4M to date

Presenter: Topher Kinsella, MD, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Xenthera Inc.

(In-Person)

Categorical Listings: Immuno-oncology, Oncology

Location: Salt Lake City, Utah United States

Year Established: 2022 **Website:** www.xenthera.com

Corporate Partners: None yet

Funds Raised: INP

Presenter: Lynne Kelley, MD, CEO & CMO

Yatiri Bio Inc

(In-Person)

Categorical Listings: Drug Discovery, Machine Learning, Oncology

Location: San Diego, California United States

Year Established: 2020 **Website:** www.yatiribio.com

Corporate Partners: Partnerships with 5 biotech/pharma companies

Funds Raised: \$2.3M Seed. \$110K DoD grant.

Presenter: Pilgrim Jackson, PhD, CEO

Zafrens

Categorical Listings: Artificial Intelligence (AI), Big Data, Drug Discovery

Location: San Diego, California United States

Year Established: 2021 **Website:** www.zafrens.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Kandaswamy (Swamy) Vijayan, PhD, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Zehna Therapeutics Inc

Categorical Listings: Cardiovascular, Fibrosis, Inflammation

Location: Cleveland, Ohio United States

Year Established: 2019 **Website:** www.zehnatx.com

Corporate Partners: Cleveland Clinic

Funds Raised: \$6.2M

Presenter: Camilla V Simpson, MSc, CEO

(In-Person)

Zucara Therapeutics Inc.

Categorical Listings: Endocrine-Metabolic

Location: Toronto, Ontario Canada


Year Established: 2014 **Website:** www.zucara.ca

Corporate Partners: Seeking investors and pharma partners for later stage clinical development.

Funds Raised: Nearly \$30M in capital. \$21M was raised in a Series A financing completed in 2020.

Presenter: Michael Midmer, MSc, MBA, CEO

(In-Person)



THE 15TH ANNUAL

BIOTECH SHOWCASE™

CATEGORICAL LISTINGS

Antibodies

Abion Inc

TOC

Adagene

BTS-P

Angany inc.

BTS-C

AIMEDBIO INC.

AltruBio Inc

DM-P

Ambrx Biopharma Inc.

Aqualung Therapeutics, Corp

DM-C

Baiyaphytopharm Co., Ltd

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

S-P

BiondVax Pharmaceuticals Ltd

Bio-T

S-C

Comera Life Sciences, Inc.

Desentum Oy

Elpiscience Biopharma

Enzene Biosciences Ltd.

Fzata, Inc.

G+FLAS Life Sciences, Inc.

ImaginAb Inc

Immunwork, Inc.

Inhalon Biopharma, Inc.

KBio

Latticon Antibody Therapeutics, Inc.

Lepu Biopharma Co., Ltd.

Mabyon AG

MOLCURE Inc.

NB Health Laboratory Co., Ltd

Phanes Therapeutics, Inc.

Prellis Biologics, Inc

Antibodies (continued)

Premas Biotech Pvt Ltd

Rapid Novor Inc.

RevolKa Ltd.

Sengenics Corporation, LLC

Synaffix B.V.

Tegmine Therapeutics, Inc.

Tiziana Life Sciences

Triplebar Bio

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Artificial Intelligence (AI)

1859, Inc.

Acelot

Adagene

AIMEDBIO INC.

Anima Biotech

AQUYRE Biosciences, Inc.

Arctoris Ltd

BAKX Therapeutics

BC Platforms

Biosortia Microbiomics

Boryung Co., Ltd.

Cellply Srl

Congruence Therapeutics

Curesponse Ltd.

Cytonus Therapeutics

DNA Analytics

ENHANC3D GENOMICS

First Ascent Biomedical

Artificial Intelligence (AI) (continued)

GEnTE Lifesciences Inc.

TOC

LiveCare Corp

BTS-P

MOLCURE Inc.

BTS-C

Neo Auvra Corp.

DM-P

NetTargets Inc.

DM-C

Novellia

Nutshell Therapeutics

S-P

Omniscope Limited

Ordaos Bio

PharmCADD

S-C

Presagen

Qritive

RareStone Group

RevolKa Ltd.

Rubedo Life Sciences

Smart Dental Systems

SplIntellx Inc.

Sun Genomics

T-Cypher Bio Ltd

ThinkingNode Life Science, Inc.

Triplebar Bio

Zafrens

Autoimmune

Abarceo Pharma

AffyXell Therapeutics, Co., Ltd.

AIMEDBIO INC.

Akari Therapeutics, Plc

Allergenis

AltruBio Inc

Aqualung Therapeutics, Corp

Aristea Therapeutics

Azora Therapeutics Inc

Biocytogen Pharmaceuticals Co., Ltd.

BiondVax Pharmaceuticals Ltd

Createrna Science & Technology

GEn1E Lifesciences Inc.

Immunis, Inc.

KBio

Latticon Antibody Therapeutics, Inc.

Levatio Therapeutics

MDimune

NB Health Laboratory Co., Ltd

OKYO Pharma, Limited

Omniscope Limited

Pacylex Pharmaceuticals, Inc.

Phaim Pharma

RevolKa Ltd.

SCM Lifescience

Sengenics Corporation, LLC

SFA Therapeutics, Inc.

Simcere Inc

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Autoimmune (continued)

Think Bioscience

Tiziana Life Sciences

Triplebar Bio

TOC

BTS-P

BTS-C

Big Data

a:head bio AG

Anima Biotech

Atmo Biosciences Limited

Cellino Biotech, Inc.

Combined Therapeutics Inc

Curesponse Ltd.

Cytonus Therapeutics

Emyria Limited

ENHANC3D GENOMICS

MOLCURE Inc.

Neo Auvra Corp.

Novellia

Omniscope Limited

PreciPoint GmbH

RareStone Group

Smart Dental Systems

SplIntellx Inc.

Sun Genomics

ThinkingNode Life Science, Inc.

Zafrens

DM-P

DM-C

S-P

S-C

Bioinformatics

Acelot

TOC

Allergenis

BTS-P

BC Platforms

BTS-C

Curesponse Ltd.

First Ascent Biomedical

DM-P

GEn1E Lifesciences Inc.

DM-C

NefTargets Inc.

Novellia

Rapid Novor Inc.

S-P

Sengenics Corporation, LLC

South Rampart Pharma

S-C

Sun Genomics

T-Cypher Bio Ltd

Tegmine Therapeutics, Inc.

ThinkingNode Life Science, Inc.

TwinStrand Biosciences, Inc.

Biomanufacturing

BiondVax Pharmaceuticals Ltd

Brinter Inc

CdmoGen Co., Ltd.

Cellino Biotech, Inc.

Curate Biosciences

Enzene Biosciences Ltd.

Enzyme By Design, Inc.

G+FLAS Life Sciences, Inc.

KBio

MedTherapy Biotechnology

Pyrojas Inc.

Biosimilars

Comera Life Sciences, Inc.

TOC

Enzene Biosciences Ltd.

BTS-P

G+FLAS Life Sciences, Inc.

BTS-C

N8 Medical

ROPHIBIO, INC.

DM-P

Cardiovascular

Abarceo Pharma

DM-C

Aerami Therapeutics

S-P

Brinter Inc

Bryleos

S-C

Cayuga Biotech

CB Innovations LLC

CoreTissue BioEngineering Inc.

Corstasis Therapeutics

Createrna Science & Technology

Curi Bio, Inc.

Hyloris Pharmaceuticals SA

Immunwork, Inc.

Latticon Antibody Therapeutics, Inc.

Lightship Inc.

Microvascular Therapeutics

N8 Medical

Nanjing Novlead Biotechnology Co., Ltd.

NIBEC Co., Ltd.

NOTA Laboratories Inc.

Nuevocor Pte. Ltd.

NuvOx Pharma

Orizuru Therapeutics, Inc.

Cardiovascular (continued)

Rancho Santa Fe Bio, Inc.

Regencor, Inc.

Safi Biotherapeutics

Senex Biotechnology

Sen-Jam Pharmaceutical

Think Bioscience

Vasomune Therapeutics, Inc.

VESTECK, Inc.

Zehna Therapeutics Inc

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

CNS-Neurological

α:head bio AG

Acelot

Alpha Tau Medical Ltd.

Ashvattha Therapeutics

Bexion Pharmaceuticals, Inc.

Biosortia Microbiomics

Bioxodes SA

Bloom Science, Inc.

BrainStorm Cell Therapeutics

Congruence Therapeutics

Emyria Limited

Enveric Biosciences

HEALIOS K.K.

Healis Therapeutics, Inc

Herantis Pharma Plc

Hoba Therapeutics

ILLIAS Biologics Inc.

iN Therapeutics

iQure Pharma Inc.

<i>CNS-Neurological (continued)</i>	
KeifeRx LLC	TOC
Lipocine Inc.	BTS-P
Mabylon AG	BTS-C
MDimune	DM-P
Mediphage Bioceuticals, Inc.	DM-C
Mitoimmune Therapeutics Inc.	S-P
Modality.ai	S-C
Monument Therapeutics Limited	
Neo Auvra Corp.	
Neuraly Inc.	
Neuvivo, Inc.	
NIBEC Co., Ltd.	
NuvOx Pharma	
OYE Therapeutics Inc	
Prazer Therapeutics	
Psilera Inc.	
RareStone Group	
Reunion Neuroscience Inc.	
ReviR Therapeutics, Inc	
RUMI Scientific, Inc.	
Samsara Therapeutics Inc.	
SapiensBio Inc.	
Seal Rock Therapeutics, Inc.	
Simcere Inc	
SomaServe Limited	
South Rampart Pharma	
Spiral Therapeutics, Inc.	
TargTex S.A.	
Tiziana Life Sciences	

CNS-Neurological (continued)

Tonix Pharmaceuticals Holding Corp

Trevi Therapeutics, Inc.

Tryp Therapeutics, Inc

TOC

BTS-P

BTS-C

Contract Drug Development

Brinter Inc

CdmoGen Co., Ltd.

First Ascent Biomedical

LIFT BioSciences Ltd

Lightship Inc.

DM-P

DM-C

S-P

S-C

Contract Manufacturing

CdmoGen Co., Ltd.

MedTherapy Biotechnology

Dermatology

Adora Life Science

Alpha Tau Medical Ltd.

Arch Therapeutics

Aristea Therapeutics

Azora Therapeutics Inc

Bimini Health Tech

Connect Biopharma Holdings Limited

Healis Therapeutics, Inc

Immunomic Therapeutics, Inc.

Lightship Inc.

N8 Medical

NanoViricides, Inc.

Phaim Pharma

Dermatology (continued)

Processa Pharmaceuticals

TOC

QBiotics Group Limited

BTS-P

Quthero Inc

BTS-C

Relief Therapeutics Holding SA

Rubedo Life Sciences

DM-P

SCM Lifescience

SFA Therapeutics, Inc.

DM-C

Diagnostics

AccuraGen

S-P

AIM Biotech

S-C

Akadeum Life Sciences

Alia BioTech Holdings Limited

Allergenis

Atmo Biosciences Limited

AQUYRE Biosciences, Inc.

Biometrix Technology Co., Ltd.

Bio-T

Body Vision Medical

Calviri, Inc.

CB Innovations LLC

Cellply Srl

Coagulation Sciences

Complete Genomics

DNA Analytics

EMPIRI, Inc.

ENHANC3D GENOMICS

Juno Diagnostics

Livivos Inc

Diagnostics (continued)

Micronoma

Microvascular Therapeutics

miDiagnostics nv

Modality.ai

Newomics Inc.

Phoenix Molecular Designs Ltd.

PreciPoint GmbH

Qritive

Rapid Novor Inc.

Smart Dental Systems

Splntellx Inc.

Todos Medical Ltd.

Travera, Inc.

TwinStrand Biosciences, Inc.

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Drug Delivery

Adocia Inc.

Aerami Therapeutics

Amplicore Inc.

Atmo Biosciences Limited

Atriva Therapeutics GmbH

BioEclipse Therapeutics

Biometrix Technology Co., Ltd.

Bond Biosciences, Inc.

Comera Life Sciences, Inc.

Cytonus Therapeutics

Fzata, Inc.

ILLIAS Biologics Inc.

Immunwork, Inc.

invIOs GmbH

Drug Delivery (continued)

Lipocine Inc.	TOC
Locate Bio Ltd	BTS-P
MDimune	BTS-C
Nanjing Novlead Biotechnology Co., Ltd.	DM-P
NanoViricides, Inc.	DM-C
NIBEC Co., Ltd.	S-P
NOTA Laboratories Inc.	S-C
PharmCADD	
QurCan Therapeutics Inc.	
Radiance Therapeutics, Inc.	
Radiopharm Theranostics	
Regenosine, Inc	
SomaServe Limited	
Spiral Therapeutics, Inc.	
TargTex S.A.	
Tatara Therapeutics, Inc.	
Tegmine Therapeutics, Inc.	
VerImmune Inc	
Watershed Therapeutics	

Drug Discovery

1859, Inc.
α:head bio AG
Aardvark Therapeutics
AIM Biotech
Ambrx Biopharma Inc.
AMD Therapeutics LLC
Anima Biotech
Aptose Biosciences Inc.

Drug Discovery (continued)

Arctoris Ltd

TOC

AUM Biosciences Pte Ltd

BTS-P

Bantam Pharmaceutical LLC

BTS-C

Biocytogen Pharmaceuticals Co., Ltd.

DM-P

BioEclipse Therapeutics

DM-C

Biometrix Technology Co., Ltd.

Bloom Science, Inc.

Bond Biosciences, Inc.

Calviri, Inc.

S-P

Congruence Therapeutics

Connect Biopharma Holdings Limited

S-C

Curi Bio, Inc.

DNA Analytics

EMPIRI, Inc.

Emyria Limited

FloraWorks

ID4Pharma

Immunis, Inc.

IN8bio

KeifeRx LLC

Lassogen, Inc.

Lepu Biopharma Co., Ltd.

Levatio Therapeutics

Mabylon AG

MelliCell, Inc

NefTargets Inc.

Ochre Bio

Ordaos Bio

OROX BioSciences, Inc.

Pan Cancer T B.V.	TOC
PharmCADD	
Phoenix Molecular Designs Ltd.	BTS-P
Prazer Therapeutics	
Prellis Biologics, Inc	BTS-C
PRISM BioLab Co., Ltd.	
Psilera Inc.	DM-P
QBiotics Group Limited	
Reunion Neuroscience Inc.	DM-C
SapiensBio Inc.	
South Rampart Pharma	S-P
TargTex S.A.	
T-Cypher Bio Ltd	S-C
Think Bioscience	
Yatiri Bio Inc	
Zafrens	

Endocrine-Metabolic

1859, Inc.
Aardvark Therapeutics
Abarceo Pharma
Actimed Therapeutics Ltd.
Adocia Inc.
Aerami Therapeutics
Bryleos
Enzyme By Design, Inc.
Lipocine Inc.
MelliCell, Inc
Ochre Bio
Orizuru Therapeutics, Inc.

Endocrine-Metabolic (continued)

Pano Therapeutics, Inc.

Phaim Pharma

Relief Therapeutics Holding SA

Seal Rock Therapeutics, Inc.

Sen-Jam Pharmaceutical

Zucara Therapeutics Inc.

Epigenetic

Aptose Biosciences Inc.

EpiAxis Therapeutics

Fibrosis

Alveolus Bio

Aqualung Therapeutics, Corp

Bridge Biotherapeutics, Inc

Certa Therapeutics

ILLIAS Biologics Inc.

Kernal Bio

Livivos Inc

NB Health Laboratory Co., Ltd

Ochre Bio

OROX BioSciences, Inc.

Pano Therapeutics, Inc.

PRISM BioLab Co., Ltd.

SapiensBio Inc.

Seal Rock Therapeutics, Inc.

SFA Therapeutics, Inc.

Trevi Therapeutics, Inc.

Zehna Therapeutics Inc



Functional Genomics

Bantam Pharmaceutical LLC

TOC

Gastrointestinal

Aardvark Therapeutics

Alpha Tau Medical Ltd.

AQUYRE Biosciences, Inc.

Azora Therapeutics Inc

Bond Biosciences, Inc.

Chimeric Therapeutics

EnteroBiotix

Fzata, Inc.

Jaguar Health, Inc.

Processa Pharmaceuticals

SAB Biotherapeutics, Inc.

SCM Lifescience

Sen-Jam Pharmaceutical

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Gene-Cell Therapy

Adocia Inc.

AffyXell Therapeutics, Co., Ltd.

AIM Biotech

Akadeum Life Sciences

Amplo Biotechnology

Autonomous Therapeutics, Inc.

Avectas

BioEclipse Therapeutics

BrainStorm Cell Therapeutics

Carina Biotech

Carmine Therapeutics

Gene-Cell Therapy (continued)

Cellino Biotech, Inc.	TOC
Cellply Srl	BTS-P
Chimeric Therapeutics	BTS-C
CiMaas	DM-P
Connect Biopharma Holdings Limited	DM-C
Curate Biosciences	S-P
Curi Bio, Inc.	S-C
Gilboa Therapeutics, Inc.	
HEALIOS K.K.	
Immunis, Inc.	
IN8bio	
LIFT BioSciences Ltd	
Mediphage Bioceuticals, Inc.	
MedTherapy Biotechnology	
Mesoblast Limited	
Microvascular Therapeutics	
miDiagnostics nv	
Minovia Therapeutics	
Morphocell Technologies inc.	
Nuevocor Pte. Ltd.	
OncoPep, Inc.	
Opus Genetics	
Orizuru Therapeutics, Inc.	
Pan Cancer T B.V.	
Pyrojas Inc.	
QurCan Therapeutics Inc.	
Safi Biotherapeutics	
SIRPant Immunotherapeutics Inc.	
SomaServe Limited	

TwinStrand Biosciences, Inc.

TOC

VC Cell Therapy

Visgenx, Inc.

BTS-P

Generics

BTS-C

Complete Genomics

DM-P

Genomics

DM-C

Complete Genomics

S-P

Hematology

S-C

Akari Therapeutics, Plc

Aptose Biosciences Inc.

Arovella Therapeutics

Bantam Pharmaceutical LLC

Cayuga Biotech

Chimeric Therapeutics

CiMaas

Coagulation Sciences

Cyclacel Pharmaceuticals, Inc.

Deka Biosciences, Inc

ID4Pharma

Lepu Biopharma Co., Ltd.

Mediphage Bioceuticals, Inc.

Minovia Therapeutics

PreciPoint GmbH

Safi Biotherapeutics

Hepatic

Bryleos

EnteroBiotix

HEALIOS K.K.

Livivos Inc

Morphocell Technologies inc.

OROX BioSciences, Inc.

SteroTherapeutics, LLC

TOC

BTS-P

BTS-C

DM-P

DM-C

Immunology

Adiso Therapeutics Inc

AffyXell Therapeutics, Co., Ltd.

Akadeum Life Sciences

Akari Therapeutics, Plc

AltruBio Inc

Angany inc.

Aristea Therapeutics

Ashvattha Therapeutics

Biosortia Microbiomics

Cartherics Pty Ltd

Certa Therapeutics

Circio AB

Combined Therapeutics Inc

Deka Biosciences, Inc

Desentum Oy

Immodulon Therapeutics Ltd

Inhalon Biopharma, Inc.

Levatio Therapeutics

Minovia Therapeutics

Neuvivo, Inc.

S-P

S-C

Immunology (continued)

Nutshell Therapeutics

TOC

OKYO Pharma, Limited

BTS-P

Pacylex Pharmaceuticals, Inc.

BTS-C

Pan Cancer T B.V.

PhotonPharma Inc

DM-P

Prellis Biologics, Inc

Pyrojas Inc.

DM-C

SAB Biotherapeutics, Inc.

Synaffix B.V.

S-P

Todos Medical Ltd.

Tonix Pharmaceuticals Holding Corp

S-C

Vernagen, LLC

Immuno-oncology

Activate Therapeutics

Adagene

Angany inc.

Autonomous Therapeutics, Inc.

AIVITA Biomedical, Inc.

Ambrx Biopharma Inc.

Anixa Biosciences

Arovella Therapeutics

AUM Biosciences Pte Ltd

Avectas

Bexion Pharmaceuticals, Inc.

Baiyaphytopharm Co., Ltd

Brenus Pharma

Carina Biotech

Immuno-oncology (continued)

Cartherics Pty Ltd

TOC

CiMaas

BTS-P

Circio AB

BTS-C

Combined Therapeutics Inc

Curate Biosciences

DM-P

Elpiscience Biopharma

EpiAxis Therapeutics

DM-C

GeoVax Labs, Inc.

Gilboa Therapeutics, Inc.

S-P

ID4Pharma

ImaginAb Inc

S-C

Immunomic Therapeutics, Inc.

invIOs GmbH

Kernal Bio

KORTUC Inc.

LIFT BioSciences Ltd

MAIA Biotechnology, Inc.

miDiagnostics nv

Nectin Therapeutics

NeolImmuneTech, Inc.

Nutshell Therapeutics

NuvOx Pharma

OncoPep, Inc.

Phanes Therapeutics, Inc.

PhotonPharma Inc

Premas Biotech Pvt Ltd

QurCan Therapeutics Inc.

Simcere Inc

SIRPant Immunotherapeutics Inc.

Synaffix B.V.	TOC
VerImmune Inc	
Xenthera Inc.	BTS-P
<i>Infectious Disease</i>	BTS-C
Abion Inc	DM-P
Activate Therapeutics	
Aeolian Biotechnology Corp.	DM-C
AIVITA Biomedical, Inc.	
ALiA BioTech Holdings Limited	S-P
Anixa Biosciences	
Atriva Therapeutics GmbH	S-C
Autonomous Therapeutics, Inc.	
Baiyaphytopharm Co., Ltd	
ExpreS2ion Biotech Holding AB	
Inhalon Biopharma, Inc.	
Kernal Bio	
NanoViricides, Inc.	
NOTA Laboratories Inc.	
SAB Biotherapeutics, Inc.	
Tonix Pharmaceuticals Holding Corp	
Valley Fever Solutions	
Vasomune Therapeutics, Inc.	
Vernagen, LLC	
Watershed Therapeutics	

Inflammation

Adiso Therapeutics Inc

Adora Life Science

Alveolus Bio

BrainStorm Cell Therapeutics

Bridge Biotherapeutics, Inc

Chrysalis BioTherapeutics, Inc.

Createrna Science & Technology

Deka Biosciences, Inc

Desentum Oy

Mesoblast Limited

Mitoimmune Therapeutics Inc.

Nanjing Novlead Biotechnology Co., Ltd.

Neuvivo, Inc.

OKYO Pharma, Limited

Reglagene, Inc.

Rubedo Life Sciences

Spiral Therapeutics, Inc.

VESTECK, Inc.

Zehna Therapeutics Inc

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Machine Learning

Arctoris Ltd

BAKX Therapeutics

Body Vision Medical

CB Innovations LLC

Ordaos Bio

Presagen

Qritive

Yatiri Bio Inc

Microarrays

Alia BioTech Holdings Limited

Calviri, Inc.

TOC

BTS-P

Microbiome

Adiso Therapeutics Inc

Alveolus Bio

Bloom Science, Inc.

Enterobiotix

List Biotherapeutics

Micronoma

BTS-C

DM-P

DM-C

S-P

S-C

Mitochondrial Therapeutic

Mitoimmune Therapeutics Inc.

Pano Therapeutics, Inc.

Musculoskeletal

Adora Life Science

Amplicore Inc.

Amplio Biotechnology

Locate Bio Ltd

Rancho Santa Fe Bio, Inc.

Regenosine, Inc

Neurology

Ashvattha Therapeutics

Caergen Therapeutics, LLC

Herantis Pharma Plc

iN Therapeutics

iQure Pharma Inc.

Modality.ai

Monument Therapeutics Limited

OYE Therapeutics Inc

Prazer Therapeutics

Samsara Therapeutics Inc.

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Neuropathy

Amplio Biotechnology

Bexion Pharmaceuticals, Inc.

Hoba Therapeutics

iQure Pharma Inc.

Osmol Therapeutics, Inc.

Samsara Therapeutics Inc.

Oncology

Abion Inc

AccuraGen

Actimed Therapeutics Ltd.

Aelin Therapeutics

AnHeart Therapeutics

Anixa Biosciences

Arovella Therapeutics

AUM Biosciences Pte Ltd

BAKX Therapeutics

BioCity Biopharma	TOC
Boryung Co., Ltd.	
Brenus Pharma	BTS-P
Bridge Biotherapeutics, Inc	
Cairn Therapeutics Inc	BTS-C
Carina Biotech	
Cartherics Pty Ltd	DM-P
Circio AB	
Concarlo Therapeutics Inc.	DM-C
Cyclacel Pharmaceuticals, Inc.	S-P
Ellipses Pharma Ltd	
Elpiscience Biopharma	S-C
EMPIRI, Inc.	
Enzyme By Design, Inc.	
EpiAxis Therapeutics	
ExpreS2ion Biotech Holding AB	
Gilboa Therapeutics, Inc.	
ImaginAb Inc	
Immodulon Therapeutics Ltd	
Immunomic Therapeutics, Inc.	
IN8bio	
IONIQ Sciences	
Jaguar Health, Inc.	
Kintara Therapeutics, Inc.	
KORTUC Inc.	
Lassogen, Inc.	
Micronoma	
Molecular Templates	
Osmol Therapeutics, Inc.	

Oncology (continued)

Pacylex Pharmaceuticals, Inc.

Panavance Therapeutics Inc.

Phanes Therapeutics, Inc.

Phoenix Molecular Designs Ltd.

PhotonPharma Inc

Pimera Therapeutics

Premas Biotech Pvt Ltd

PRISM BioLab Co., Ltd.

Processa Pharmaceuticals

QBiotics Group Limited

Radiopharm Theranostics

Reglagene, Inc.

ReviR Therapeutics, Inc

Senex Biotechnology

Shorla Oncology

SIRPant Immunotherapeutics Inc.

SteroTherapeutics, LLC

Tatara Therapeutics, Inc.

Travera, Inc.

Viewpoint Molecular Targeting

Xenthera Inc.

Yatiri Bio Inc

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Ophthalmic

AMD Therapeutics LLC

Caeregen Therapeutics, LLC

Carmine Therapeutics

Opus Genetics

Radiance Therapeutics, Inc.

ROPHIBIO, INC.

VC Cell Therapy

Visgenx, Inc.

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Orphan-Rare Disease

Actimed Therapeutics Ltd.

AnHeart Therapeutics

Bioxodes SA

Caeregen Therapeutics, LLC

Carmine Therapeutics

Cayuga Biotech

Certa Therapeutics

Immodulon Therapeutics Ltd

Jaguar Health, Inc.

Nuevocor Pte. Ltd.

OncoPep, Inc.

Opus Genetics

Rancho Santa Fe Bio, Inc.

ReviR Therapeutics, Inc

RUMI Scientific, Inc.

SteroTherapeutics, LLC

Valley Fever Solutions

Vasomune Therapeutics, Inc.

Other

CoreTissue BioEngineering Inc.

Hyloris Pharmaceuticals SA

KORTUC Inc.

LiveCare Corp

OYE Therapeutics Inc

Personalized Medicine

AIVITA Biomedical, Inc.

BC Platforms

Bimini Health Tech

Coagulation Sciences

invIOs GmbH

IONIQ Sciences

Juno Diagnostics

Monument Therapeutics Limited

Newomics Inc.

Presagen

Tatara Therapeutics, Inc.

Travera, Inc.

Viewpoint Molecular Targeting

Platform Technology

Aelin Therapeutics

Arch Therapeutics

Avectas

Body Vision Medical

Brenus Pharma

iN Therapeutics

Lassogen, Inc.

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

LiveCare Corp	TOC
MelliCell, Inc	
Newomics Inc.	BTS-P
Psilera Inc.	
VerImmune Inc	BTS-C
VESTECK, Inc.	DM-P

Pulmonary

Chrysalis BioTherapeutics, Inc.	DM-C
Corstasis Therapeutics	S-P
Relief Therapeutics Holding SA	
Trevi Therapeutics, Inc.	S-C

Regenerative Medicine

Amplicore Inc.
Arch Therapeutics
Bimini Health Tech
Chrysalis BioTherapeutics, Inc.
Locate Bio Ltd
Morphocell Technologies inc.
Regencor, Inc.
Regenosine, Inc

Renal

BioCity Biopharma
Corstasis Therapeutics
RUMI Scientific, Inc.

Reproductive Medicine

Juno Diagnostics

TOC

Vaccines

Aeolian Biotechnology Corp.

ExpreS2ion Biotech Holding AB

GeoVax Labs, Inc.

Vernagen, LLC

BTS-P

BTS-C

DM-P

DM-C

Women's Health

Concarlo Therapeutics Inc.

Hyloris Pharmaceuticals SA

Watershed Therapeutics

S-P

S-C

A black and white photograph of the Golden Gate Bridge, viewed from a low angle looking across the water towards the towers. The bridge's suspension cables and towers are prominent. The sky is overcast. A white diagonal line cuts across the bottom right of the image.

**DIGITAL & MEDTECH
MEDICINE & SHOWCASE**

**PRESENTING COMPANY
PROFILES**

Alpenglow Biosciences, Inc.

(In-Person)

TOC

Categorical Listings: Artificial Intelligence (AI), Big Data, Bioinformatics

Location: Seattle, Washington United States

Year Established: 2018 **Website:** www.alpenglowbiosciences.com

Corporate Partners: Imaging: partnered with Hamamatsu to develop a turnkey device.
Tissue/data access: Multiple partnerships with contract research organizations and biobanks to provide 3D imaging services to shared pharma customers

Funds Raised: More than \$5M total with \$4M in June 2021 (first priced round), \$4.5M convertible note currently open.

Presenter: Nicholas (Nick) Reder, MD, MPH, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Altoida

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, CNS-Neurological

Location: Washington, D.C., United States

Year Established: 2016 **Website:** www.altoida.com

Corporate Partners: Large pharma, Eisai

Funds Raised: \$20.3 Series A

Presenter: Travis Bond, MBA, CEO

Breathe BioMedical

(In-Person)

Categorical Listings: Diagnostics, Machine Learning, Oncology

Location: Moncton, New Brunswick Canada

Year Established: 2015 **Website:** www.breathebiomedical.com

Corporate Partners: Horizon Health Network, New Brunswick Health Research Foundation

Funds Raised: \$14M dilutive funding to date. \$5M non-dilutive funding to date.

Presenter: Stephen (Steve) Graham, PhD, CEO

Cordance Medical, Inc.

(In-Person)

Categorical Listings: Antibodies, CNS-Neurological, Diagnostics

Location: Mountain View, California United States

Year Established: 2018 **Website:** www.cordancemedical.com

Corporate Partners: The company has partnerships with undisclosed pharma partners.

Funds Raised: \$7.5M

Presenter: Ryan Dittamore, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

EverEx

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Musculoskeletal, Platform Technology

Location: Seoul, South Korea

Year Established: 2019 **Website:** www.everex.kr

Corporate Partners: Seoul National University Bundang Hospital, Samsung Electronics, Aju Pharm, ezCaretech

Funds Raised: \$4M including \$1.5M in grant.

Presenter: Chan (Alex) Yoon, PhD, MSc, CEO

Flow Neuroscience Inc.

(In-Person)

Categorical Listings: Neurology, Personalized Medicine, Platform Technology

Location: Malmo, Sweden

Year Established: 2016 **Website:** www.flowneuroscience.com

Corporate Partners: The company is running pilots with the NHS in the UK and one of the largest hospital providers in the US.

Funds Raised: \$12.6M to date with \$8.5M in May 2021 in Flow's Series A round (led by Khosla Ventures).

Presenter: Erin Lee, CEO

Gyder Surgical Pty Ltd

(In-Person)

Categorical Listings: Musculoskeletal**Location:** Palo Alto, California United States**Year Established:** 2018 **Website:** www.gydersurgical.com**Corporate Partners:** Gyder has partnered with Hydrix in developing the product.**Funds Raised:** INP**Presenter:** Sujit Dike, MS, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

HealthBeacon PLC (Euronext Growth Dublin:HBCN)

(In-Person)

Categorical Listings: Autoimmune, Cardiovascular, Dermatology**Location:** Dublin, Ireland**Year Established:** 2013 **Website:** www.healthbeacon.com**Corporate Partners:** HealthBeacon partners with Hamilton Beach to offer its Injection Care Management System direct to consumers.**Funds Raised:** INP**Presenter:** Jim Joyce, MBA, CEO**Neola Medical AB** (OtherSTO:NEOLA)

(In-Person)

Categorical Listings: Diagnostics, Pulmonary**Location:** Lund, Sweden**Year Established:** 2016 **Website:** www.neolamedical.com**Corporate Partners:** Seeking corporate partner for U.S. launch in order to scale fast to Neonatal Intensive Care Units (more than 22,000 relevant U.S. NICU beds).**Funds Raised:** INP**Presenter:** Hanna Sjöström, MBA, CEO

NeoLight, LLC

(In-Person)

Categorical Listings: Contract Manufacturing, Diagnostics, Ophthalmic

Location: Scottsdale, Arizona United States

Year Established: 2016 **Website:** www.theneolight.com

Corporate Partners: Honor Health, Dignity Health, Catholic Health and Arizona State University

Funds Raised: \$22M in capital to date (as of Dec 2022). Won \$1M+ of non-dilutive-grant and award funding.

Presenter: Vivek Kopparthi, MS, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

NeoPrediX

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Diagnostics, Machine Learning

Location: Ft. Lauderdale, Florida United States

Year Established: 2020 **Website:** www.neopredix.com

Corporate Partners: INP

Funds Raised: \$7M in a Seed round.

Presenter: Thorsten Waloschek, MBA, CEO

Nervonik, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Neuropathy

Location: Los Angeles, California United States

Year Established: 2020 **Website:** www.nervonik.com

Corporate Partners: None

Funds Raised: \$1.65M

Presenter: Barry Keenan, PhD, MBA, CEO

NeuraLace Medical, Inc.

(In-Person)

TOC

Categorical Listings: Neurology, Other

Location: San Diego, California United States

Year Established: 2016 **Website:** www.neuralacemedical.com

Corporate Partners: The company has a scientific advisory board comprising of the following physicians: Dr. Leonardo Kapural and Dr. Dawood Sayed.

Funds Raised: Total to date \$11.6M, looking to raise \$12M for Series A.

Presenter: Keith Warner, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Orthox Limited

(In-Person)

Categorical Listings: Musculoskeletal, Regenerative Medicine

Location: Abingdon, United Kingdom

Year Established: 2009 **Website:** www.orthox.co.uk

Corporate Partners: Orthopaedic pipeline co-development and China market approval programmes with undisclosed major strategic partners

Funds Raised: Over \$28M: \$12.5M in Series A investment; \$4.5M in convertible notes; \$11.5M in grant funding.

Presenter: Nick Skaer, PhD, CEO

PreciPoint GmbH

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Dermatology, Diagnostics

Location: Freising, Germany

Year Established: 2018 **Website:** www.precipoint.com

Corporate Partners: Nikon as Distributor

Funds Raised: \$20M

Presenter: Dennis Julian Vermeulen, Business Innovation Manager

SIME Diagnostics Limited

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Diagnostics

Location: London, United Kingdom

Year Established: 2014 **Website:** www.simedx.com

Corporate Partners: SIME has a public private partnership agreement with the Danish healthcare system (unique cost free patient access) plus hospital partners in the US and UK.

Funds Raised: £8M raised to date, 50% of which has been non dilutive funding from EU Horizon2020 and Microsoft Ventures.

Presenter: Povl Verder, CEO



Strados Labs

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Cardiovascular, Diagnostics

Location: Philadelphia, Pennsylvania United States

Year Established: 2016 **Website:** www.stradoslabs.com

Corporate Partners: Customers are major pharmaceutical companies using RESP in clinical trials and large health systems using RESP in remote disease management.

Funds Raised: \$9.1M to date in early-stage venture and Angel financing as well as \$1.5M in grant funding.

Presenter: Nicholas (Nick) Shane Delmonico, CEO

Virility Medical

(In-Person)

Categorical Listings: Other

Location: Hod Hasharon, Israel

Year Established: 2016 **Website:** www.virilitymedical.com

Corporate Partners: In discussions with major North American drug store chains. Further pipeline partnerships with companies like Reckitt and Church & Dwight.

Funds Raised: \$20M since 2016, \$10M in 2022.

Presenter: David (Dudi) Salton, CEO

Vocxi Health

(In-Person)

TOC

Categorical Listings: Artificial Intelligence (AI), Big Data, CNS-Neurological

Location: Arden Hills, Minnesota United States

Year Established: 2022 **Website:** www.vocxihealth.com

Corporate Partners: This company is a spin of Boston Scientific and it has spent over \$11M to develop this technology. They own about 8% of the company.

Funds Raised: Just opened a \$5M Seed round. The company is about half way and looking for new investors.

Presenter: Ping Yeh, MBA, MME, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

VoxCell BioInnovation Inc.

(In-Person)

Categorical Listings: Drug Discovery, Oncology, Platform Technology

Location: Victoria, British Columbia Canada

Year Established: 2020 **Website:** www.voxcellbio.com

Corporate Partners: Currently in conversations with BC Cancer Agency and J&J.

Funds Raised: \$500K in 2021, \$2M in 2022.

Presenter: Karolina Valente, PhD, CEO & CSO



**DIGITAL & MEDTECH
MEDICINE & SHOWCASE**

CATEGORICAL LISTINGS

Antibodies

Cordance Medical, Inc.

TOC

Artificial Intelligence (AI)

Alpenglow Biosciences, Inc.

BTS-P

Altoida

BTS-C

EverEx

DM-P

NeoPrediX

DM-C

PreciPoint GmbH

S-P

SIME Diagnostics Limited

Strados Labs

S-C

Vocxi Health

Autoimmune

HealthBeacon PLC

Big Data

Alpenglow Biosciences, Inc.

Altoida

SIME Diagnostics Limited

Vocxi Health

Bioinformatics

Alpenglow Biosciences, Inc.

Cardiovascular

HealthBeacon PLC

Strados Labs

CNS-Neurological

Altoida

Cordance Medical, Inc.

Nervonik, Inc.

Vocxi Health

Contract Manufacturing

Neolight, LLC

Dermatology

HealthBeacon PLC

Diagnostics

Breathe BioMedical

Cordance Medical, Inc.

Neola Medical AB

NeoPrediX

PreciPoint GmbH

Diagnostics

Neolight, LLC

PreciPoint GmbH

SIME Diagnostics Limited

Strados Labs

Drug Discovery

VoxCell BioInnovation Inc.

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Machine Learning

Breathe BioMedical

NeoPrediX

TOC

BTS-P

Musculoskeletal

EverEx

Gyder Surgical Pty Ltd

Orthox Limited

BTS-C

DM-P

DM-C

Neurology

Flow Neuroscience Inc.

NeuraLace Medical, Inc.

S-P

S-C

Neuropathy

Nervonik, Inc.

Oncology

Breathe BioMedical

VoxCell BioInnovation Inc.

Ophthalmic

Neolight, LLC

Other

NeuraLace Medical, Inc.

Virility Medical

Personalized Medicine

Flow Neuroscience Inc.

Platform Technology

EverEx

Flow Neuroscience Inc.

VoxCell BioInnovation Inc.

Pulmonary

Neola Medical AB

Regenerative Medicine

Orthox Limited

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

A black and white photograph of the Golden Gate Bridge, viewed from a low angle looking across the water towards the bridge's towers. The bridge's suspension cables and towers are prominent against a dark, overcast sky. The water is calm, and the distant city skyline is visible on the horizon. A white diagonal line cuts across the bottom right of the image, separating the photograph from a solid grey background.

SEED SHOWCASE

**PRESENTING COMPANY
PROFILES**

Akelos Inc.

Categorical Listings: Neuropathy

Location: New York, New York United States

Year Established: 2019 **Website:** www.akelosinc.com

Corporate Partners: INP

Funds Raised: Seed of \$1M.

Presenter: Steven Fox, DDS, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Alteron Therapeutics Inc

Categorical Listings: CNS-Neurological, Pulmonary

Location: Cedarhurst, New York United States

Year Established: 2021 **Website:** www.alterontherapeutics.com

Corporate Partners: Currently developing the drugs independently.

Funds Raised: \$1M

Presenter: Chengliang Zhang, PhD, Founder

(In-Person)

Amaro Therapeutics, Inc.

Categorical Listings: Endocrine-Metabolic, Inflammation, Platform Technology

Location: New York, New York United States

Year Established: 2021 **Website:** www.amarotx.com

Corporate Partners: None

Funds Raised: INP

Presenter: Michael French, MS, CEO

(In-Person)

Aperture Therapeutics, Inc.

(In-Person)

TOC

Categorical Listings: CNS-Neurological, Drug Discovery, Functional Genomics

Location: San Carlos, California United States

Year Established: 2022 **Website:** www.aperturetx.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Martin Jacko, PhD, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Aplife Biotech

(In-Person)

Categorical Listings: Diagnostics, Personalized Medicine, Platform Technology

Location: Miami, Florida United States

Year Established: 2020 **Website:** www.aplifebiotech.com

Corporate Partners: Product is being developed in partnership with Synopsis, Intense Engineering, Silicon Catalyst, and Dayton University.

Funds Raised: \$2M in cash and an estimation of \$3M in-kind partner services (for the development of semiconductor).

Presenter: Guido Tomás Rozenblum, PhD, Co-Founder & CSO

Artificial Axon Labs

(Virtual)

Categorical Listings: CNS-Neurological, Drug Discovery, Platform Technology

Location: Topsfield, Massachusetts United States

Year Established: 2022 **Website:** www.artificialaxonlabs.com

Corporate Partners: Currently in discussions with several potential strategic partners.

Funds Raised: INP

Presenter: Anna Jagielska, PhD, MSc, Founder, President & CEO

Audax Therapeutics

(In-Person)

Categorical Listings: Fibrosis, Inflammation, Pulmonary

Location: Edinburgh, United Kingdom

Year Established: 2022 **Website:** www.audaxtx.com

Corporate Partners: The company's technology has been developed jointly between Heriot Watt University, Edinburgh, Scotland and the University of Texas Medical Branch.

Funds Raised: To date, the project has enjoyed >\$5M in grant funding. Audax seeks its first Seed round in 2023.

Presenter: Chris Wardhaugh, MBA, Founder

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Bask Health

(In-Person)

Categorical Listings: Big Data, Generics, Other

Location: New York, New York United States

Year Established: 2021 **Website:** www.bask.bio

Corporate Partners: INP

Funds Raised: INP

Presenter: Zachary Dorf, Founder & CEO

BCN Biosciences

(In-Person)

Categorical Listings: Drug Discovery, Gastrointestinal, Hepatic

Location: Inglewood, California United States

Year Established: 2020 **Website:** www.bcnbio.com

Corporate Partners: Informal presentations to Lilly & Merck recently.

Funds Raised: Less than \$1M

Presenter: Sudip (Deep) Chakraborty, MBA, Co-Founder & CEO

Bespoke Biotherapeutics LLC

(In-Person)

TOC

Categorical Listings: Drug Delivery, Gene-Cell Therapy, Immunology**Location:** San Carlos, California United States**Year Established:** 2021 **Website:** www.bespokebiotx.com**Corporate Partners:** None**Funds Raised:** NSF SBIR and founder funding.**Presenter:** Steven R Deitcher, MD, Founder, CEO & Chairman

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Bio-stream Diagnostics Inc

(In-Person)

Categorical Listings: Diagnostics, Infectious Disease, Inflammation**Location:** Edmonton, Alberta Canada**Year Established:** 2020 **Website:** www.bio-stream.ca**Corporate Partners:** LabCorp and Dynalife are lab companies with some limited support.**Funds Raised:** About \$1.5M**Presenter:** John Murphy, CEO**CancerFree Biotech Ltd.**

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Drug Discovery, Gene-Cell Therapy**Location:** Jersey City, New Jersey United States**Year Established:** 2019 **Website:** www.cancerfree.io**Corporate Partners:** Cooperated with 44 medical institutes and up to 69 physicians in Taiwan. Signed contracts and built partnerships with Japan (100 cases) and China (800 cases).**Funds Raised:** INP**Presenter:** Po Han (Po) Chen, CEO

Captain T Cell

(Virtual)

Categorical Listings: Drug Discovery, Gene-Cell Therapy, Immunology

Location: Berlin, Germany

Year Established: 2022 **Website:** INP

Corporate Partners: INP

Funds Raised: \$5.5M in non-dilutive grants during academic pre-Seed phase. Now raising for independent operations.

Presenter: Felix Lorenz, PhD, CEO



Cedience

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Bioinformatics

Location: Toronto, Ontario Canada

Year Established: 2019 **Website:** www.cedience.com

Corporate Partners: Select biopharmaceutical teams representing top 20 pharma, mid-sized biopharma and small biotech joined Cedience's early adopter program to guide the development of the technology.

Funds Raised: \$1M pre-Seed round.

Presenter: Amin Osmani, MS, CEO

Celine Therapeutics

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Bioinformatics

Location: Boston, Massachusetts United States

Year Established: 2021 **Website:** celinetx.com

Corporate Partners: 1 major pharmaceutical company for the pilot study for AI platform (press release will be in early January) and 2 research institutes for partnership (legal process)

Funds Raised: \$300K (\$150K grants) including a major pharmaceutical and VCs.

Presenter: Nina Keshavarzi, Co-Founder & CEO

Chiima Therapeutics

Categorical Listings: Dermatology, Neurology, Neuropathy

Location: Rockville, Maryland United States

Year Established: 2021 **Website:** www.chiimatherapeutics.com

Corporate Partners: INP

Funds Raised: \$250K

Presenter: Peter (Pete) Isikwe, PharmD, Founder & CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

CovInnovations

Categorical Listings: Drug Discovery, Immunology, Infectious Disease

Location: Las Vegas, Nevada United States

Year Established: 2021 **Website:** www.covinnovations.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Aury Nagy, MD, Founder, Executive Chairman & CSO

(In-Person)

Cura Therapeutics

Categorical Listings: Immunology, Immuno-oncology, Infectious Disease

Location: Berkeley, California United States

Year Established: 2020 **Website:** www.curatherapeutics.com

Corporate Partners: Lead asset CT101 is being developed with CROs and CDMO partners (undisclosed).

Funds Raised: \$1.55M venture capital and an additional \$350K in non-dilutive funding to date.

Presenter: Claudia Penafuerte, PhD, Co-Founder & CEO

(In-Person)

Cyteph

(In-Person)

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Oncology

Location: Brisbane, Australia

Year Established: Planned 2023 **Website:** www.qimrberghofer.edu.au

Corporate Partners: Prospective spin-out company from Prof. Rajiv Khanna's lab at QIMR Berghofer Medical Research Institute. The institute also has a cGMP cell therapy manufacturing facility QGen Cell Therapeutics.

Funds Raised: Grant funding and QIMR Berghofer commercialisation-accelerator funds only.

Presenter: Melissa Knight, PhD, MBA, Consultant & CEO NewCo



Diadem Biotherapeutics

(In-Person)

Categorical Listings: Immunology, Immuno-oncology, Platform Technology

Location: Torrance, California United States

Year Established: 2020 **Website:** www.diadembio.com

Corporate Partners: The company is seeking Biopharma partnerships.

Funds Raised: \$1.6M to date. \$1.2M round led by Novateur Ventures in Q3 2021.

Presenter: Mickey Pentecost, PhD, CEO

Dionysus Digital Health, Inc.

(In-Person)

Categorical Listings: Diagnostics, Epigenetic, Machine Learning

Location: San Diego, California United States

Year Established: 2020 **Website:** www.dionysushealth.com

Corporate Partners: None

Funds Raised: \$200K in pre-Seed financing from the Co-Founders.

Presenter: Andrea Cubitt, PhD, CEO

Duet BioTherapeutics

(In-Person)

Categorical Listings: Immuno-oncology, Oncology, Other

Location: Pasadena, California United States

Year Established: 2021 **Website:** www.duettx.com

Corporate Partners: No corporate partners

Funds Raised: INP

Presenter: Alan Horsager, PhD, President, CEO, & Director



Endure Biotherapeutics, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Endocrine-Metabolic, Gastrointestinal

Location: Encinitas, California United States

Year Established: 2018 **Website:** www.endurebio.com

Corporate Partners: In late stage discussions with "The Leader" in PKU therapeutics for the first program. This is an early stage collaboration.

Funds Raised: INP

Presenter: Mark S. Wilson, MBA, CEO

Entelexo Biotherapeutics

(In-Person)

Categorical Listings: Autoimmune, CNS-Neurological, Immunology

Location: Irvine, California United States

Year Established: 2020 **Website:** www.entelexo.com

Corporate Partners: Not currently partnered with any other corporations, and all IP is independently owned by Entelexo.

Funds Raised: INP

Presenter: Milad Riazifar, PhD, Co-Founder & CEO

Grannus Therapeutics, Inc.

Categorical Listings: Oncology

Location: Indianapolis, Indiana United States

Year Established: 2019 **Website:** INP

Corporate Partners: Grannus does not currently have corporate partners.

Funds Raised: INP

Presenter: John Foglesong, MBA, President & CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Guardian Bio Inc.

Categorical Listings: Gene-Cell Therapy, Immunology, Immuno-oncology

Location: Boston, Massachusetts United States

Year Established: 2022 **Website:** www.guardian-bio.com

Corporate Partners: Manufacturing partner: Charles River Laboratory

Funds Raised: INP

Presenter: Ananya Zutshi, MS, MBA, CEO

(In-Person)

H42.inc

Categorical Listings: Bioinformatics, Diagnostics, Epigenetic

Location: Foster City, California United States

Year Established: 2021 **Website:** h42.ai

Corporate Partners: The company currently has collaborations with longevity-focused research institutions (University of Ghent, faculty of Medicine and Health Sciences; Cancer Research Institute Ghent (CRIG) and wellness and fitness companies.

Funds Raised: Pre-Seed round of \$500K in 2022.

Presenter: Sonja Blaauw, MS, CEO

(In-Person)

HDAX Therapeutics

(In-Person)

TOC

Categorical Listings: Drug Discovery, Mitochondrial Therapeutic, Neuropathy

Location: Toronto, Ontario Canada

Year Established: 2020 **Website:** www.hdaxtx.com

Corporate Partners: In discussion with some big pharma.

Funds Raised: \$700K in pre-Seed.

Presenter: Nabanita Nawar, PhD, Co-Founder & CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

HelloBiome (ELSI Skin Health Inc.)

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Big Data, Dermatology

Location: San Francisco, California United States

Year Established: 2018 (launched HelloBiome 2022) **Website:** www.hellobio.me

Corporate Partners: Confidential

Funds Raised: \$1.8M

Presenter: Elsa Jungman, PhD, CEO

Ilios Therapeutics, Inc.

(In-Person)

Categorical Listings: CNS-Neurological, Drug Delivery, Drug Discovery

Location: Cambridge, Massachusetts United States

Year Established: 2022 **Website:** www.iliostx.com

Corporate Partners: The company plans on doing the drug discovery phase ahead of the FDA IND application to go into human clinical trials. Plans on partnering with other players after Phase I.

Funds Raised: INP

Presenter: Luca Gianì, MPP, Co-Founder & CEO

Immunyx Pharma

(In-Person)

Categorical Listings: Autoimmune, Drug Delivery, Gastrointestinal

Location: New York, New York United States

Year Established: 2021 **Website:** www.immunyx.com

Corporate Partners: The company has established research partnerships with Merck KGaA in LNP-mRNA delivery and J&J/BARDA in respiratory disease treatment.

Funds Raised: \$1.75M to date from investors.

Presenter: Seth Salpeter, PhD, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

InGel Therapeutics

(In-Person)

Categorical Listings: CNS-Neurological, Drug Delivery, Gene-Cell Therapy

Location: Allston, Massachusetts United States

Year Established: 2022 **Website:** www.ingeltx.com

Corporate Partners: Key partnership will be developed in the next 12 months.

Funds Raised: \$1M pre-Seed funding over the last 6 months. Goal is to raise \$10-15M in the follow-on Seed round.

Presenter: Pierre Dromel, PhD, CEO

InnovaRegi, LLC

(In-Person)

Categorical Listings: Drug Discovery, Personalized Medicine, Platform Technology

Location: San Jose, California United States

Year Established: 2019 **Website:** INP

Corporate Partners: Exclusive license from the University of Texas System.

Funds Raised: More than \$800K in NIH and University of Texas grants, and \$300K from Founders.

Presenter: John Wiktorowicz, PhD, CEO

Lime Therapeutics

(In-Person)

Categorical Listings: CNS-Neurological, Drug Discovery, Oncology

Location: New York, New York United States

Year Established: 2021 **Website:** www.limetherapeutics.com

Corporate Partners: In talks with multiple corporate partners for co-development of drugs for lead target and beyond.

Funds Raised: \$2.6M Seed + \$1.5M in NIH grant funding awarded to Co-Founders for Lime technology prior to start of company.

Presenter: Shardule Shah, PhD, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

MeCo Diagnostics

(In-Person)

Categorical Listings: Diagnostics, Fibrosis, Genomics

Location: San Diego, California United States

Year Established: 2022 **Website:** www.mecodiagnosics.com

Corporate Partners: The company has a LOI from Genomic Testing Cooperative to commercialize its product as part of their portfolio of clinical genomics services.

Funds Raised: INP

Presenter: Adam Watson, PhD, Co-Founder & CEO

MedaSystems

(In-Person)

Categorical Listings: Platform Technology, Research Tools

Location: Menlo Park, California United States

Year Established: 2021 **Website:** www.medasystems.com

Corporate Partners: Biopharma and life science companies, primarily in the oncology, rare disease and neurodegenerative space.

Funds Raised: INP

Presenter: Fiona Smythe, CEO

MedGene Therapeutics

(In-Person)

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Oncology

Location: Gaithersburg, Maryland United States

Year Established: 2019 **Website:** www.medgenetx.com

Corporate Partners: No corporate partners currently.

Funds Raised: INP

Presenter: Yong (Henry) Park, MD, CEO



Merlin Biotech, Inc.

(In-Person)

Categorical Listings: Immuno-oncology, Infectious Disease, Orphan-Rare Disease

Location: Doylestown, Pennsylvania United States

Year Established: 2022 **Website:** www.merlinbiotech.com

Corporate Partners: Baruch S. Blumberg Institute for development of a chronic hepatitis B vaccine and a major East Coast university for development of a Lyme disease vaccine.

Funds Raised: INP

Presenter: Randall N. Hyer, MD, PhD, MPH, CEO

Mermaid Bio GmbH

(In-Person)

Categorical Listings: Antibodies, Drug Discovery, Fibrosis

Location: Munich, Germany

Year Established: 2022 **Website:** www.mermaid.bio

Corporate Partners: None

Funds Raised: Funding to date has come from founders and non-dilutive research contract.

Presenter: Ranja Salvamoser, PhD, MS, Executive Director

Metanoia Bio, Inc.

(In-Person)

Categorical Listings: Cardiovascular, Endocrine-Metabolic, Ophthalmic

Location: Los Angeles, California United States

Year Established: 2019 **Website:** INP

Corporate Partners: Working with Eurofins, The Jackson Laboratory, Inscopix, and others to progress internal programs forward.

Funds Raised: Less than \$2M to date (Pre-Seed) from Angels and company founders.

Presenter: Slavica Tudzarova, PhD, Co-Founder

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

MitoRx Therapeutics Limited

(In-Person)

Categorical Listings: CNS-Neurological, Drug Discovery, Mitochondrial Therapeutic

Location: Didcot, United Kingdom

Year Established: 2021 **Website:** www.mitorxtherapeutics.com

Corporate Partners: MitoRx is developing relationships with several potential corporate partners.

Funds Raised: Initial Seed financing raised.

Presenter: Jonathan (Jon) Rees, PhD, CEO

Neurovascular Research and Design

(In-Person)

Categorical Listings: Artificial Intelligence (AI), CNS-Neurological, Diagnostics

Location: Tucson, Arizona United States

Year Established: 2019 **Website:** www.neurovrd.com

Corporate Partners: Clinical testing will be performed at Johns Hopkins University.

Funds Raised: Bootstrapped pre-Seed funding

Presenter: Nicholas Chung, CTO

NKILT Therapeutics

(In-Person)

Categorical Listings: Gene-Cell Therapy, Hematology, Immuno-oncology

Location: Springfield, New Jersey United States

Year Established: 2021 **Website:** www.nkilt.com

Corporate Partners: INP

Funds Raised: Pre-Seed raise ongoing with target of \$1.5M, \$400K already raised.

Presenter: Raphaël (Rapha) G. Ognar, MSc, MBA, Co-Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

OncoRx Insights, Inc.

(In-Person)

Categorical Listings: INP

Location: Boulder, Colorado United States

Year Established: 2021 **Website:** www.oncorxinsights.com

Corporate Partners: Carolina Blood and Cancer Clinic, Chareslston, SC

Funds Raised: Total funding \$537K, including non-dilutive grants and founder funds.

Presenter: Dave Parkhill, Co-Founder & CEO

Palm Therapeutics, Inc.

(In-Person)

Categorical Listings: Drug Discovery, Oncology, Platform Technology

Location: San Diego, California United States

Year Established: 2019 **Website:** www.palmtherapeutics.com

Corporate Partners: Partnership discussions around palmitoylation inhibitor discovery for partner targets are ongoing.

Funds Raised: Awarded >\$1M in SBIR grants from the National Institutes of Health (NCI & NINDS).

Presenter: Andrew Rudd, PhD, Co-Founder & CSO

Parallel Health, Inc.

(In-Person)

TOC

Categorical Listings: Dermatology, Diagnostics, Microbiome

Location: San Francisco, California United States

Year Established: 2020 **Website:** www.parallelhealth.io

Corporate Partners: Illumina

Funds Raised: \$1.8M

Presenter: Natalise Kalea Robinson, MBA, CEO

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Propelle Therapeutics, Inc.

(In-Person)

Categorical Listings: Drug Delivery, Immuno-oncology, Oncology

Location: San Diego, California United States

Year Established: 2020 **Website:** INP

Corporate Partners: Currently in proprietary collaborations with the National Cancer Institute/NIH, the Manchester Breast Centre at the University of Manchester, and the Sanger Institute at Cambridge University.

Funds Raised: Internally funded by Co-Founders thus far.

Presenter: Rajiv Datar, PhD, Co-Founder & CEO

PTM Therapeutics, Inc.

(In-Person)

Categorical Listings: Antibodies, Drug Discovery, Gastrointestinal

Location: San Mateo, California United States

Year Established: 2019/2020 **Website:** www.ptmthera.com

Corporate Partners: None

Funds Raised: INP

Presenter: Jennifer Cheng, PhD, CEO

QUANTiSCOPE

Categorical Listings: Artificial Intelligence (AI), Big Data, Drug Discovery

Location: Cambridge, Massachusetts United States

Year Established: 2022 **Website:** www.imaging.bio

Corporate Partners: Undisclosed pharma partnerships

Funds Raised: \$10K in grants

Presenter: Kevin Christopher, MBA, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

RADIO USA, Inc.

Categorical Listings: Antibodies, Autoimmune, Dermatology

Location: Wilmington, Delaware United States

Year Established: 2020 **Website:** www.radbiopharm.com

Corporate Partners: INP

Funds Raised: \$1.135M; \$980K dilutive funds; \$155K non-dilutive funds.

Presenter: Daniel Flores, MD, CEO

(Virtual)

RenuMemo Therapeutics

Categorical Listings: Neurology

Location: Buford, Georgia United States

Year Established: 2022 **Website:** www.renumemo.com

Corporate Partners: INP

Funds Raised: No funds have been raised yet.

Presenter: Hong Ye, PhD, CEO

(In-Person)

Resonantia Diagnostics, Inc

(In-Person)

Categorical Listings: Diagnostics, Infectious Disease, Platform Technology

Location: Dallas, Texas United States

Year Established: 2020 **Website:** INP

Corporate Partners: None

Funds Raised: INP

Presenter: Matthew (Matt) Jones, MBA, Founder & CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Respirogen Inc.

(Virtual)

Categorical Listings: Drug Delivery, Pulmonary

Location: Boulder, Colorado United States

Year Established: 2018 **Website:** www.respirogen.com

Corporate Partners: None

Funds Raised: Angel investment of \$1.25M; State of Colorado Advanced Industries grant of \$250K (2020); US Air Force research contract \$400K (2020).

Presenter: Robert Scribner, MBA, CEO

ResVita Bio

(In-Person)

Categorical Listings: Autoimmune, Dermatology, Gene-Cell Therapy

Location: Berkeley, California United States

Year Established: 2021 **Website:** www.resvitabio.com

Corporate Partners: None. AbbVie awarded ResVita Bio a "Golden Ticket" as a promising technology for treatment of skin diseases.

Funds Raised: A little over \$1M in dilutive and non-dilutive funds.

Presenter: Amin Zargar, PhD, MS, CEO

Rezq Bio

(In-Person)

Categorical Listings: Autoimmune, Endocrine-Metabolic, Gene-Cell Therapy

Location: Pittsburgh, Pennsylvania United States

Year Established: 2021 **Website:** www.rezq.bio

Corporate Partners: Significant ongoing discussions. Funding and partnership efforts just began in Nov '22.

Funds Raised: INP

Presenter: Arjun (Arjun) Hattiangadi, MS, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Scaffold Therapeutics Inc.

(In-Person)

Categorical Listings: Drug Discovery, Epigenetic, Immuno-oncology

Location: Boston, Massachusetts United States

Year Established: 2022 **Website:** www.scaffoldtx.com

Corporate Partners: In advanced partnership negotiations with multiple companies.

Funds Raised: INP

Presenter: Jeffrey (Jeff) Carter, Founder & CEO

Soof Solutions Inc.

(In-Person)

Categorical Listings: Artificial Intelligence (AI), Bioinformatics, CNS-Neurological

Location: Alameda, California United States

Year Established: 2021 **Website:** www.soofsolutions.com

Corporate Partners: None

Funds Raised: \$100K; Includes Angel investors and NSF ICorps Program.

Presenter: Maheen Mausoo Adamson, PhD, Co-Founder & CEO

Synergy Therapeutics Inc

(In-Person)

Categorical Listings: Drug Delivery, Immunology, Oncology

Location: Bronx, New York United States

Year Established: 2021 **Website:** INP

Corporate Partners: BusStim LLC is a risk-sharing Virtual Biotech Accelerator.

Funds Raised: Founders' Laboratories are both active developing theranostic tools and testing tumors for synergy.

Presenter: Jerome Schentag, PharmD, Founder & CSO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Synlico Inc.

(In-Person)

Categorical Listings: Bioinformatics, Drug Discovery, Gene-Cell Therapy

Location: Burlingame, California United States

Year Established: 2021 **Website:** www.synlico.com

Corporate Partners: INP

Funds Raised: INP

Presenter: Jingwei Lu, PhD, Founder & CEO

Tenomix Inc.

(In-Person)

Categorical Listings: Gastrointestinal, Machine Learning, Oncology

Location: London, Ontario Canada

Year Established: 2021 **Website:** www.tenomix.com

Corporate Partners: Platform technology is being developed and validated with a leading Canadian university and marquee hospitals from various Canadian and US cities.

Funds Raised: \$425K in non-dilutive funding in the last 15 months.

Presenter: Saumik Biswas, PhD, CEO

Tesarakt Inc

Categorical Listings: Artificial Intelligence (AI), Big Data, Bioinformatics

Location: Palo Alto, California United States

Year Established: 2022 **Website:** www.tesarakt.com

Corporate Partners: In discussions with several corporate partners (stealth).

Funds Raised: \$0.5M

Presenter: Kris Vulgan, MA, CEO

(In-Person)

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Therafast Bio

Categorical Listings: Immuno-oncology, Oncology

Location: Lyon, France

Year Established: 2019 **Website:** INP

Corporate Partners: The company does not have corporate partners - yet.

Funds Raised: INP

Presenter: Erwan Eriau, PhD, MBA, President

(In-Person)

Transcera Inc.

Categorical Listings: Drug Delivery, Endocrine-Metabolic, Gastrointestinal

Location: Cambridge, Massachusetts United States

Year Established: 2021 **Website:** www.transcera.com

Corporate Partners: Bench space at LabCentral is sponsored by Novo Nordisk.

Funds Raised: \$1M in pre-Seed venture capital and \$250K in cash grants and uncapped, no discount SAFEs.

Presenter: Hunter Goble, MBA, CEO

(In-Person)

Unison Medicines, Inc

(In-Person)

Categorical Listings: Infectious Disease

Location: Cambridge, Massachusetts United States

Year Established: 2020 **Website:** INP

Corporate Partners: Scientific work is in collaboration with Vernalis Research (Cambridge, UK).

Funds Raised: More than \$1.3M in Seed funding from institutions and biotech insiders.

Presenter: Peter (Doug) Witt, MS, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

VacV Biotherapeutics (UK) Ltd

(In-Person)

Categorical Listings: Biomanufacturing, CNS-Neurological, Gene-Cell Therapy

Location: London, United Kingdom

Year Established: 2022 **Website:** www.vacvbtx.com

Corporate Partners: INP

Funds Raised: \$3M Seed funding.

Presenter: Glyn Edwards, MSc, Executive Chair

Vine Medical

(In-Person)

Categorical Listings: Platform Technology

Location: Goleta, California United States

Year Established: 2021 **Website:** www.vinemed.com

Corporate Partners: None

Funds Raised: INP

Presenter: David Haggerty, CEO

Validus Cellular Therapeutics, Inc.

(In-Person)

Categorical Listings: Gene-Cell Therapy, Immunology, Infectious Disease**Location:** Aurora, Colorado United States**Year Established:** 2019 **Website:** www.validustherapeutics.com**Corporate Partners:** Manufacturing program is being accomplished in coordination with Gencure (part of BioBridge Global) and other partners.**Funds Raised:** Approximately \$575K including enabling grant funding of \$350K, Founder funding of \$100K and external Seed financing of \$125K.**Presenter:** Ethan Mann, PhD, MBA, CEO

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

WMT AG

(In-Person)

Categorical Listings: Drug Discovery, Hematology, Immuno-oncology**Location:** Heidelberg, Germany**Year Established:** 2020 **Website:** www.wm-therapeutics.com**Corporate Partners:** none**Funds Raised:** €1.85M raised in a first Seed round early 2021 by HTGF, Viva Biotech and a list of private individuals.**Presenter:** Claus Kremoser, PhD, CEO**XM Therapeutics, Inc.**

(In-Person)

Categorical Listings: Cardiovascular, Fibrosis, Inflammation**Location:** Providence, Rhode Island United States**Year Established:** 2022 **Website:** www.xmtherapeutics.com**Corporate Partners:** None**Funds Raised:** \$500K in convertible debt for the Seed round of financing.**Presenter:** Frank Ahmann, MBA, President & CEO



SEED SHOWCASE

CATEGORICAL LISTINGS

Antibodies

Mermaid Bio GmbH

PTM Therapeutics, Inc.

RADBIO USA, Inc.

TOC

BTS-P

BTS-C

Artificial Intelligence (AI)

CancerFree Biotech Ltd.

Cedience

Celine Therapeutics

HelloBiome (ELSI Skin Health Inc.)

Neurovascular Research and Design

QUANTiSCOPE

Soof Solutions Inc.

Tesarakt Inc

DM-P

DM-C

S-P

S-C

Autoimmune

Entelexo Biotherapeutics

Immunyx Pharma

RADBIO USA, Inc.

ResVita Bio

Rezq Bio

Big Data

Bask Health

Cedience

Celine Therapeutics

HelloBiome (ELSI Skin Health Inc.)

QUANTiSCOPE

Tesarakt Inc

Bioinformatics

Cedience

Celine Therapeutics

H42.inc

Soof Solutions Inc.

Synlico Inc.

Tesarakt Inc

TOC

BTS-P

BTS-C

DM-P

DM-C

BioManufacturing

VacV Biotherapeutics (UK) Ltd

S-P

Cardiovascular

Metanoia Bio, Inc.

XM Therapeutics, Inc.

S-C

CNS-Neurological

Alteron Therapeutics Inc

Aperture Therapeutics, Inc.

Artificial Axon Labs

Endure Biotherapeutics, Inc.

Entelexo Biotherapeutics

Ilios Therapeutics, Inc.

InGel Therapeutics

Lime Therapeutics

MitoRx Therapeutics Limited

Neurovascular Research and Design

Soof Solutions Inc.

VacV Biotherapeutics (UK) Ltd

Dermatology

Chiima Therapeutics

HelloBiome (ELSI Skin Health Inc.)

Parallel Health, Inc.

RADBIO USA, Inc.

ResVita Bio

TOC

BTS-P

BTS-C

DM-P

Diagnostics

Aplife Biotech

Bio-stream Diagnostics Inc

Dionysus Digital Health, Inc.

H42.inc

MeCo Diagnostics

Neurovascular Research and Design

Parallel Health, Inc.

Resonantia Diagnostics, Inc

DM-C

S-P

S-C

Drug Delivery

Bespoke Biotherapeutics LLC

Ilios Therapeutics, Inc.

Immunyx Pharma

InGel Therapeutics

Propelle Therapeutics, Inc.

Respirogen Inc.

Synergy Therapeutics Inc

Transcera Inc.

Drug Discovery

Aperture Therapeutics, Inc.

Artificial Axon Labs

BCN Biosciences

CancerFree Biotech Ltd.

Captain T Cell

CovInnovations

HDAX Therapeutics

Ilios Therapeutics, Inc.

InnovaRegi, LLC

Lime Therapeutics

Mermaid Bio GmbH

MitoRx Therapeutics Limited

Palm Therapeutics, Inc.

PTM Therapeutics, Inc.

QUANTiSCOPE

Scaffold Therapeutics Inc.

Synlico Inc.

WMT AG

TOC

BTS-P

BTS-C

DM-P

DM-C

S-P

S-C

Endocrine-Metabolic

Amaro Therapeutics, Inc.

Endure Biotherapeutics, Inc.

Metanoia Bio, Inc.

Rezq Bio

Transcera Inc.

Epigenetic

Dionysus Digital Health, Inc.

H42.inc

Scaffold Therapeutics Inc.

Fibrosis

Audax Therapeutics

MeCo Diagnostics

Mermaid Bio GmbH

XM Therapeutics, Inc.

TOC

BTS-P

BTS-C

Gastrointestinal

BCN Biosciences

Endure Biotherapeutics, Inc.

Immunyx Pharma

PTM Therapeutics, Inc.

Tenomix Inc.

Transcera Inc.

DM-P

DM-C

S-P

S-C

Gene-Cell Therapy

Bespoke Biotherapeutics LLC

CancerFree Biotech Ltd.

Captain T Cell

Cyteph

Guardian Bio Inc.

InGel Therapeutics

MedGene Therapeutics

NKILT Therapeutics

ResVita Bio

Rezq Bio

Synlico Inc.

VacV Biotherapeutics (UK) Ltd

Validus Cellular Therapeutics, Inc.

Generics

Bask Health

Genomics

MeCo Diagnostics

TOC

Hepatic

BCN Biosciences

BTS-P

Hematology

NKILT Therapeutics

BTS-C

WMT AG

DM-P

DM-C

Immunology

Bespoke Biotherapeutics LLC

S-P

Captain T Cell

S-C

CovInnovations

Cura Therapeutics

Diadem Biotherapeutics

Entelexo Biotherapeutics

Guardian Bio Inc.

Synergy Therapeutics Inc

Validus Cellular Therapeutics, Inc.

Immuno-oncology

Cura Therapeutics

Cyteph

Diadem Biotherapeutics

Duet BioTherapeutics

Guardian Bio Inc.

MedGene Therapeutics

Merlin Biotech, Inc.

NKILT Therapeutics

Propelle Therapeutics, Inc.

Scaffold Therapeutics Inc.

TOC

Therafast Bio

WMT AG

BTS-P

Infectious Disease

BTS-C

Bio-stream Diagnostics Inc

DM-P

CovInnovations

DM-C

Cura Therapeutics

Merlin Biotech, Inc.

Resonantia Diagnostics, Inc

S-P

Unison Medicines, Inc

Validus Cellular Therapeutics, Inc.

S-C

Inflammation

Amaro Therapeutics, Inc.

Audax Therapeutics

Bio-stream Diagnostics Inc

XM Therapeutics, Inc.

Machine Learning

Dionysus Digital Health, Inc.

Tenomix Inc.

Microbiome

Parallel Health, Inc.

Mitochondrial Therapeutic

HDAX Therapeutics

MitoRx Therapeutics Limited

Neurology

Chiima Therapeutics

RenuMemo Therapeutics

TOC

BTS-P

Neuropathy

Akelos inc.

Chiima Therapeutics

HDAX Therapeutics

BTS-C

DM-P

DM-C

Oncology

Cyteph

Duet BioTherapeutics

Grannus Therapeutics, Inc.

Lime Therapeutics

MedGene Therapeutics

Palm Therapeutics, Inc.

Propelle Therapeutics, Inc.

Synergy Therapeutics Inc

Tenomix Inc.

Therafast Bio

S-P

S-C

Orphan-Rare Disease

Merlin Biotech, Inc.

Ophthalmic

Metanoia Bio, Inc.

Other

Bask Health

Duet BioTherapeutics

Personalized Medicine

Aplife Biotech

InnovaRegi, LLC



Platform Technology

Amaro Therapeutics, Inc.

Aplife Biotech

Diadem Biotherapeutics

Artificial Axon Labs

InnovaRegi, LLC

MedaSystems

Palm Therapeutics, Inc.

Resonantia Diagnostics, Inc

Vine Medical



Pulmonary

Alteron Therapeutics Inc

Audax Therapeutics

Respirogen Inc.

Research Tools

MedaSystems

Facilitating strategic connections that drive life science dealmaking

EBD
GROUP

Build connections and forge valuable partnerships to move your company forward at one of our upcoming global partnering events.

BIO-EUROPE SPRING®

March 20–22, 2023 | Basel, Switzerland
March 28–30, 2023 | Digital
bioeurope.spring.com

ASIA BIO PARTNERING FORUM

April 2023 | Singapore
informaconnect.com/asia-bio-partnering-forum

BIO€QUITY EUROPE

May 14–16, 2023 | Dublin, Ireland
May 22–23, 2023 | Digital
informaconnect.com/bioequity-europe-2023

BIOPHARM AMERICA™

September 2023 | Raleigh, North Carolina
informaconnect.com/biopharm-america

CHINABIO® PARTNERING FORUM

September 19–21, 2023 | Shanghai, China
informaconnect.com/chinabio-partnering-forum

BIO-EUROPE®

November 6–8, 2023 | Munich, Germany
bioeurope.com

EBD ACADEMY

Enhancing key business development skills and competencies for successful partnering and to accelerate career progression.

Classes are now available for 2023
ebdacademy.com

Learn more: ebdgroup.com

Co-produced by

